KR20170028186A - Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same - Google Patents
Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same Download PDFInfo
- Publication number
- KR20170028186A KR20170028186A KR1020150125106A KR20150125106A KR20170028186A KR 20170028186 A KR20170028186 A KR 20170028186A KR 1020150125106 A KR1020150125106 A KR 1020150125106A KR 20150125106 A KR20150125106 A KR 20150125106A KR 20170028186 A KR20170028186 A KR 20170028186A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- hydroxyalkanoyl
- coa
- hydroxybutyrate
- mutated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
- C12P7/625—Polyesters of hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
- C12Y208/03—CoA-transferases (2.8.3)
- C12Y208/03001—Propionate CoA-transferase (2.8.3.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체 및 이의 제조방법, 그리고 상기 삼중합체를 생산하는 미생물 및 이의 제조방법이 제공된다.Hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, a process for their preparation, and microorganisms for the production of the terpolymers and processes for their preparation are provided.
Description
4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체 및 이의 제조방법, 그리고 상기 삼중합체를 생산하는 미생물 및 이의 제조방법이 제공된다.Hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, a process for their preparation, and microorganisms for the production of the terpolymers and processes for their preparation are provided.
폴리하이드록시알카노에트(polyhydroxyalkanoate: PHA)는 미생물이 질소, 산소, 인, 마그네슘 등의 성장에 필요한 원소가 부족한 상태에서 탄소원이 풍부하게 존재할 때 에너지 및 환원능의 저장을 위하여 미생물 내부에 축적하는 천연 폴리에스터 물질이다. PHA는 종래 석유로부터 유래된 합성 고분자와 비슷한 물성을 가지면서 생분해성 및 생체적합성을 보이기 때문에, 기존의 합성 플라스틱을 대체할 물질로 인식되고 있다. Polyhydroxyalkanoate (PHA) is a microorganism that accumulates in microorganisms for the storage of energy and reducing ability when a microorganism is abundant in a carbon source in a state in which an element necessary for growth of nitrogen, oxygen, phosphorus, It is a natural polyester material. PHA has been recognized as a substitute for conventional synthetic plastics because it exhibits similar biodegradability and biocompatibility with synthetic polymer derived from petroleum.
PHA 의 모노머로 알려진 것은 약 150종 이상으로, 이 중 대부분의 모노머들이 3-, 4-, 5- 또는 6-하이드록시알카노에트(hydroxyalkanoate: HA)이고, 활발히 연구되고 있는 대표적인 PHA 모노머로는 3-하이드록시부티레이트(3-hydroxybutyrate: 3HB), 4-하이드록시부티레이트(4-hydroxybutyrate: 4HB), 3-하이드록시프로피오네이트(3-hydroxypropionate: 3HP), 및 탄소수가 6~12개인 중간 사슬 길이(medium chain length: MCL)의 3-하이드록시알카노에트(MCL 3-hydroxyalkanoate) 등과 같이, 3번과 4번 탄소 위치에 하이드록시기(hydroxyl group)가 있는 모노머들을 들 수 있다.Most of the known monomers are PHA monomers such as 3-, 4-, 5- or 6-hydroxyalkanoate (HA), and PHA monomers which are actively studied 3-hydroxybutyrate (3HB), 4-hydroxybutyrate (4HB), 3-hydroxypropionate (3HP), and an intermediate chain having 6 to 12 carbon atoms Monomers having a hydroxyl group at
미생물에서 PHA 를 합성하는 데 핵심적인 역할을 하는 효소는 PHA 합성효소로, 이는 다양한 하이드록시아실-CoA(hydroxyacyl-CoA) 를 기질로 하여 해당 모노머를 함유한 폴리에스터를 합성한다. 또한, PHA 합성효소는 다양한 하이드록시아실-CoA 들 중에서 기질특이성을 가지기 때문에 고분자의 모노머 조성은 PHA 합성효소에 의해 조절된다. 따라서, PHA 를 합성하기 위해서는, PHA 합성효소의 기질로 사용될 수 있는 다양한 하이드록시아실-CoA 를 합성하고 제공하는 대사경로와, 상기 기질과 PHA 합성효소를 이용한 고분자 합성 대사경로가 필요하다. The enzyme that plays a key role in the synthesis of PHA in microorganisms is the PHA synthase, which synthesizes a polyester containing the corresponding hydroxyacyl-CoA (hydroxyacyl-CoA) as a substrate. In addition, since the PHA synthase has substrate specificity among various hydroxyacyl-CoA's, the monomer composition of the polymer is controlled by the PHA synthase. Therefore, in order to synthesize PHA, a metabolic pathway for synthesizing and providing various hydroxyacyl-CoA which can be used as a substrate of PHA synthesizing enzyme and a polymer synthesis metabolic pathway using the substrate and PHA synthesizing enzyme are required.
한편, 2번 탄소 위치에 하이드록시기가 있는 락테이트(lactate) 또는 2-하이드록시부티레이트(2-hydroxybutyrate, 2HB) 등의 모노머의 경우 PHA 합성효소의 기질특이성에 적합하지 않아, 자연적으로 또는 재조합적인 방법으로 PHA 및 이의 공중합체를 제조한 예가 거의 없었다. 나아가, 아직까지 2HB, 3HB 및 4HB 를 모노머로 하여 생산된 삼중합체 PHA 고분자는 보고되어 있지 않다.On the other hand, monomers such as lactate or 2-hydroxybutyrate (2HB) having a hydroxy group at the 2-carbon position are not suitable for the substrate specificity of the PHA synthase, and naturally or recombinantly There were few examples of the preparation of PHA and its copolymer. Furthermore, there has not been reported a terpolymer PHA polymer produced using 2HB, 3HB and 4HB as monomers.
이에, 본 발명은 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체 및 그 제조에 관한 기술을 제공한다.Accordingly, the present invention provides a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, and a technique for preparing the same.
일 예는, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 제공한다.An example provides a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as recurring units.
다른 예는, 락테이트 디하이드로게나아제(lactate dehydrogenase)의 활성이 약화 내지 결손되고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 폴리하이드록시알카노에트 합성효소를 코딩하는 유전자를 포함하는 미생물을 배양하는 단계를 포함하는, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체의 제조방법을 제공한다.Another example is that the activity of lactate dehydrogenase is weakened or deficient, the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 2- Hydroxyalkanoyl-CoA, converting 3-hydroxyalkanoate into 3-hydroxyalkanoyl-CoA, converting 4-hydroxyalkanoate into 4-hydroxyalkanoyl-CoA Encoding a polyhydroxyalkanoate synthase using 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA as substrates 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, comprising the step of culturing a microorganism containing the gene.
다른 예는, 락테이트 디하이드로게나아제(lactate dehydrogenase)의 활성이 약화 내지 결손되고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 포함하며, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 생산하는 미생물을 제공한다.Another example is that the activity of lactate dehydrogenase is weakened or deficient, the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 2- Hydroxyalkanoyl-CoA, a gene encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding a 2-hydroxyalkanoyl-CoA, 3-hydroxy Hydroxybutyrate, 2-hydroxybutyrate and 2-hydroxybutyrate as a substrate, and a gene encoding a PHA synthetase using as a substrate, 4-hydroxybutyrate, 3-hydroxybutyrate and 2- As well as a method for producing the same.
다른 예는, 락테이트 디하이드로게나아제(lactate dehydrogenase)를 코딩하는 유전자를 결실시키고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 세포에 도입하는 단계를 포함하는, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 생산하는 미생물의 제조방법을 제공한다.In another example, a gene encoding lactate dehydrogenase is deleted, 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate is converted to 2-hydroxyalkanoyl- Hydroxyalkanoyl-CoA, a gene encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding a 2-hydroxyalkanoyl-CoA, 3-hydroxy Hydroxybutyrate, 3-hydroxybutyrate, and 2-hydroxybutyrate, which comprises the step of introducing into a cell a gene encoding a PHA synthesizing enzyme that uses 4-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- There is provided a process for producing a microorganism which produces a terpolymer containing hydroxybutyrate as a repeating unit.
일 양태로, 본 발명은 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체 및 이의 제조방법에 관한 것이다.In one aspect, the present invention relates to a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as recurring units, and a process for its preparation.
구체적인 일 예는, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 제공한다. 예를 들어, 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체 에 관한 것이다.A specific example provides a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as recurring units. For example, 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer.
다른 예는 락테이트 디하이드로게나아제(lactate dehydrogenase)의 활성이 약화 내지 결손되고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 폴리하이드록시알카노에트합성효소를 코딩하는 유전자를 포함하는 세포를 배양하는 단계를 포함하는, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체의 제조방법에 관한 것이다.Another example is that the activity of lactate dehydrogenase is weakened or deficient, the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is replaced with 3 -Hydroxyalkanoyl-CoA and encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding an enzyme that converts 2-hydroxyalkanoyl-CoA, 3-hydroxy Comprising the step of culturing a cell comprising a gene encoding a polyhydroxyalkanoate synthase using alkanoyl-CoA and 4-hydroxyalkanoyl-CoA as a substrate, 4-hydroxybutyrate, 3- Hydroxybutyrate and 2-hydroxybutyrate as repeating units.
다른 양태로, 본 발명은 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 생산하는 미생물 및 이의 제조방법에 관한 것이다.In another aspect, the present invention relates to a microorganism producing a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, and a method for producing the same.
구체적인 일 예는, 락테이트 디하이드로게나아제(lactate dehydrogenase)의 활성이 약화 내지 결손되고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 포함하며, 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 생산하는 미생물에 관한 것이다.A specific example is that the activity of lactate dehydrogenase is weakened or deficient, the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate Hydroxyalkanoyl-CoA, and a gene encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding 2-hydroxyalkanoyl-CoA, 3- Comprising a gene encoding a PHA synthase using hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA as substrates and repeating 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate To a microorganism producing a terpolymer containing the unit as a unit.
다른 예는, 락테이트 디하이드로게나아제(lactate dehydrogenase)를 코딩하는 유전자를 결실시키고, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 세포에 도입하는 단계를 포함하는, 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 생산하는 미생물의 제조방법에 관한 것이다.In another example, a gene encoding lactate dehydrogenase is deleted, 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate is converted to 2-hydroxyalkanoyl- Hydroxyalkanoyl-CoA, a gene encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding a 2-hydroxyalkanoyl-CoA, 3-hydroxy Hydroxybutyrate-2-hydroxybutyrate-2-hydroxybutyrate-2-hydroxybutyrate, which comprises the step of introducing into a cell a gene encoding a PHA synthesizing enzyme using as a substrate hydroxybenzoyl-CoA and 4-hydroxyalkanoyl- Hydroxybutyrate < / RTI > terpolymer.
이하, 본 발명의 구성을 보다 상세하게 설명한다.Hereinafter, the configuration of the present invention will be described in more detail.
용어, "4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체" 란 모노머로서 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트가 에스터 결합으로 중합된 반복단위를 포함하는 선형의 폴리에스터를 말한다. 이 때, 각 모노머의 중합 순서에는 특별한 제한이 없으며, 무작위적으로 반복될 수 있다. 예를 들어, 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체, 3-하이드록시부티레이트-2-하이드록시부티레이트-4-하이드록시부티레이트 삼중합체, 2-하이드록시부티레이트-4-하이드록시부티레이트-3-하이드록시부티레이트 삼중합체, 4-하이드록시부티레이트-2-하이드록시부티레이트-3-하이드록시부티레이트 삼중합체, 3-하이드록시부티레이트-4-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체, 2-하이드록시부티레이트-3-하이드록시부티레이트-4-하이드록시부티레이트 삼중합체 등을 예시할 수 있다.The term "terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units" means that the monomers 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate Refers to a linear polyester comprising repeating units polymerized by ester linkage. At this time, there is no particular limitation on the order of polymerization of each monomer, and it can be randomly repeated. Hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer, 3-hydroxybutyrate-2-hydroxybutyrate-4-hydroxybutyrate terpolymer, 2-hydroxybutyrate- Hydroxybutyrate-3-hydroxybutyrate terpolymer, 4-hydroxybutyrate-2-hydroxybutyrate-3-hydroxybutyrate terpolymer, 3-hydroxybutyrate-4-hydroxybutyrate- Butyrate terpolymer, 2-hydroxybutyrate-3-hydroxybutyrate-4-hydroxybutyrate terpolymer, and the like.
용어, "2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소"는, CoA 공여체로부터 CoA 를 떼어서 2-하이드록시알카노에트, 3-하이드록시알카노에트 및 4-하이드록시알카노에트에 각각 전달함으로써 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA을 생성할 수 있는 효소를 말한다. 상기 CoA 공여체로는 아세틸-CoA 또는 아실-CoA (예를 들어, 프로피오닐-CoA 등)를 예시할 수 있다.The term "2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoate Quot; is an enzyme that converts CoA from a CoA donor to 2-hydroxyalkanoate, 3-hydroxyalkanoate and 4-hydroxyalkanoate, respectively, to convert 2-hydroxyalkanoyl- -Hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA. Examples of the CoA donor include acetyl-CoA or acyl-CoA (e.g., propionyl-CoA).
일 구현예로, 상기 효소는 프로피오닐-CoA 트랜스퍼라아제일 수 있다. 또한,상기 효소의 유전자는 클로스트리디움 프로피오니쿰(Clostridium propionicum) 에서 유래한 것일 수 있다.In one embodiment, the enzyme may be a propionyl-CoA transferase. In addition, the gene of the enzyme may be derived from Clostridium propionicum.
예를 들어, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자는,For example, conversion of 2-hydroxyalkanoate to 2-hydroxyalkanoyl-CoA, conversion of 3-hydroxyalkanoate to 3-hydroxyalkanoyl-CoA, conversion of 4-hydroxyalkanoyl- The gene encoding an enzyme that converts et to 4-hydroxyalkanoyl-
(a) 서열번호 1의 염기서열; (a) a nucleotide sequence of SEQ ID NO: 1;
(b) 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열; (b) a base sequence in which A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(c) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이된 염기서열; (c) a base sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(d) 서열번호 1과 대응하는 아미노산 서열에서 Gly335Asp이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;(d) a base sequence in which Gly335Asp is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(e) 서열번호 1과 대응하는 아미노산 서열에서 Ala243Thr이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;(e) a base sequence in which Ala243Thr is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(f) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Gly이 변이되고, 서열번호 1 의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;(f) a base sequence in which Asp65Gly is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(g) 서열번호 1과 대응하는 아미노산 서열에서 Asp257Asn이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;(g) a nucleotide sequence in which Asp257Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(h) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Asn이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;(h) a nucleotide sequence in which Asp65Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(i) 서열번호 1과 대응하는 아미노산 서열에서 Thr199Ile이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열; 및(i) a base sequence in which Thr199Ile is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1; And
(j) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이되고, 서열번호 1과 대응하는 아미노산 서열에서 Val193Ala이 변이된 염기서열(j) a nucleotide sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1 and Val193Ala is mutated in the amino acid sequence corresponding to SEQ ID NO: 1
로 이루어진 군으로부터 선택된 염기서열을 갖는 것일 수 있다.≪ RTI ID = 0.0 > and / or < / RTI >
용어, " 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소"는, 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA을 기질로 하여 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 합성할 수 있는 효소를 말한다.The term "PHA synthesizing enzyme using 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA as a substrate" refers to 2-hydroxyalkanoyl-CoA, 3 -Hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA as substrates and synthesizing a terpolymer containing 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units Enzyme.
예를 들어, 상기 효소는 슈도모나스 속 6-19(pseudomonas sp. 6-19)에서 유래한 PHA 합성효소(phaC)일 수 있다.For example, the enzyme may be a PHA synthase (phaC) derived from Pseudomonas sp. 6-19 (Pseudomonas sp. 6-19).
예를 들어, 상기 PHA 합성효소는,For example, the PHA synthesizing enzyme may be,
서열번호 4의 아미노산 서열; 또는 The amino acid sequence of SEQ ID NO: 4; or
서열번호 4의 아미노산 서열에서 L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R 및 A527S로 구성되는 군으로부터 선택되는 하나 이상의 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것일 수 있다.At least one mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R and A527S in the amino acid sequence of SEQ ID NO: And a nucleotide sequence corresponding to the amino acid sequence of SEQ ID NO:
다른 구체예에서, 상기 PHA 합성효소는,In another embodiment, the PHA synthetase is selected from the group consisting of:
서열번호 4의 아미노산 서열에서, In the amino acid sequence of SEQ ID NO: 4,
(i) S325T 및 Q481M; (i) S325T and Q481M;
(ii) E130D, S325T 및 Q481M; (ii) E130D, S325T and Q481M;
(iii) E130D, S325T, S477R 및 Q481M; (iii) E130D, S325T, S477R and Q481M;
(iv) E130D, S477F 및 Q481K; 및(iv) E130D, S477F and Q481K; And
(v) L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K 및 A527S로 이루어진 군으로부터 선택되는 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것일 수 있다.(v) a nucleotide sequence corresponding to an amino acid sequence comprising a mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K and A527S.
상기 효소들은 분자의 활성을 전체적으로 변경시키지 않는 범위 내에서 추가적인 변이를 포함할 수 있다. 예를 들어, 분자의 활성을 전체적으로 변경시키지 않는 단백질 및 펩티드에서의 아미노산 교환은 당해 분야에 공지되어 있다. 예를 들어, 통상적으로 일어나는 교환은 아미노산 잔기 Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly 간의 교환을 들 수 있으나, 이에 제한되는 것은 아니다. 경우에 따라서, 상기 단백질은, 인산화(phosphorylation), 황화(sulfation), 아크릴화(acrylation), 당화(glycosylation), 메틸화(methylation), 파네실화(farnesylation) 등으로 수식(modification) 될 수도 있다. 또한, 아미노산 서열 상의 변이 또는 수식에 의해서 단백질의 열, pH 등에 대한 구조적 안정성이 증가하거나 단백질 활성이 증가한 효소 단백질을 포함할 수 있다.The enzymes may contain additional mutations within the scope of not totally altering the activity of the molecule. For example, amino acid exchanges in proteins and peptides that do not globally alter the activity of the molecule are known in the art. For example, the commonly occurring exchanges are carried out with amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / , Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu and Asp / Gly exchange. In some cases, the protein may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, or the like. In addition, it may include an enzyme protein whose structural stability against protein heat, pH, etc. is increased or protein activity is increased by mutation or modification of amino acid sequence.
또한, 상기 효소를 코딩하는 유전자는, 기능적으로 균등한 코돈 또는 (코돈의 축퇴성에 의해) 동일한 아미노산을 코딩하는 코돈, 또는 생물학적으로 균등한 아미노산을 코딩하는 코돈을 포함하는 핵산분자를 포함할 수 있다. 상기 핵산 분자는 표준 분자 생물학 기술, 예를 들어 화학적 합성 방법 또는 재조합 방법을 이용하여 분리 또는 제조하거나, 시판되는 것을 사용할 수 있다.In addition, the gene encoding the enzyme may comprise a nucleic acid molecule comprising a functionally equivalent codon or a codon encoding the same amino acid (by codon degeneracy), or a codon encoding a biologically equivalent amino acid have. The nucleic acid molecule may be isolated or prepared using standard molecular biology techniques, for example, a chemical synthesis method or a recombinant method, or a commercially available nucleic acid molecule may be used.
용어, "락테이트 디하이드로게나아제(lactate dehydrogenase)"는 피루브산과 락테이트 간의 가역적 변환을 촉매하는 효소를 말하며, 락테이트 합성 경로에서 필수적인 역할을 한다. 일 구체예로, 상기 락테이트 디하이드로게나아제를 코딩하는 유전자는 ldhA 일 수 있다.The term "lactate dehydrogenase" refers to an enzyme that catalyzes the reversible conversion between pyruvate and lactate, and plays an essential role in the lactate synthesis pathway. In one embodiment, the gene encoding the lactate dehydrogenase may be ldhA.
본원에서는 락테이트가 포함되지 않은 공중합체를 생산하기 위하여, 숙주 세포의 대사과정 중 락테이트 생산에 관여하는 락테이트 디하이드로게나아제의 활성이 내재적 조절 활성에 비하여 약화 또는 결손됨을 특징으로 한다. 내재적 조절 활성이란 숙주 세포가 천연의 상태로 가지고 있는 효소의 활성 상태를 의미하는 것으로, 예를 들어, 대장균이 천연적으로 가지고 있는 락테이트 합성에 관한 활성을 의미할 수 있다.In the present invention, lactate dehydrogenase, which is involved in the production of lactate during the metabolism of the host cell, is characterized in that the activity of the lactate dehydrogenase is weakened or deficient compared to the intrinsic control activity, in order to produce a lactate-free copolymer. The intrinsic regulatory activity means the active state of an enzyme that the host cell has in its natural state, and may mean, for example, an activity relating to the lactate synthesis naturally occurring in Escherichia coli.
락테이트 디하이드로게나아제 활성의 결손은, 상기 효소를 코딩하는 유전자의 일부 또는 전부를 결실 또는 치환하거나 상기 유전자의 염기서열 내에 특정 변이서열을 삽입하는 등의 유전자 조작에 의하여 수행될 수 있다. 이 때 당업계에 알려진 통상의 넉아웃 기술을 적용할 수 있다. 또한, 락테이트 디하이드로게나아제 활성의 약화는, 상기 유전자의 프로모터 부위 또는 5'-UTR 부위 등 유전자의 발현 조절 서열의 염기서열을 변형시킴으로써 효소의 발현을 약화시키거나, 해당 유전자의 오픈 리딩 프레임 부위에 변이를 도입함으로써 효소의 활성을 약화시킬 수 있다. 이러한 변이의 도입은, 당업계에 알려진 임의의 방법, 예를 들면, 상동 재조합, 또는 람다 레드 재조합 시스템 (lambda red recombination system)에 의하여 이루어질 수 있다.The deletion of the lactate dehydrogenase activity can be carried out by genetic manipulation such as deletion or substitution of a part or all of the gene encoding the enzyme or insertion of a specific mutation sequence into the nucleotide sequence of the gene. Conventional knockout techniques known in the art can be applied at this time. In addition, the activity of lactate dehydrogenase may be weakened by modifying the base sequence of the expression regulatory sequence of the gene such as the promoter region or the 5'-UTR region of the gene to weaken the expression of the enzyme, By introducing a mutation at the site, the activity of the enzyme can be weakened. The introduction of such a mutation can be by any method known in the art, for example by homologous recombination, or by a lambda red recombination system.
본원에서 제공하는 미생물은, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 포함하고 있으며, 상기 유전자들이 유전자 재조합적 방법으로 세포 내에 도입되어 있는 것일 수 있다.The microorganisms provided herein convert 2-hydroxyalkanoate to 2-hydroxyalkanoyl-CoA, convert 3-hydroxyalkanoate to 3-hydroxyalkanoyl-CoA, A gene encoding an enzyme that converts a Roxy alkanoate to a 4-hydroxyalkanoyl-CoA, and a gene encoding 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- And a gene encoding a PHA synthase used as a substrate, and the genes may be introduced into cells by a recombinant method.
예를 들어, 상기 미생물은, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 재조합 벡터로 형질전환하거나 상기 유전자가 염색체상에 삽입되도록 유전자 조작된 것일 수 있다.For example, the microorganism converts 2-hydroxyalkanoate to 2-hydroxyalkanoyl-CoA, converts 3-hydroxyalkanoate to 3-hydroxyalkanoyl-CoA, A gene encoding an enzyme that converts hydroxyalkanoate into 4-hydroxyalkanoyl-CoA, and a gene encoding 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA, and 4-hydroxyalkanoyl-CoA Which is used as a substrate, may be transformed with a recombinant vector or genetically engineered such that the gene is inserted on the chromosome.
또한, 상기 미생물은, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자 중 1종을 이미 포함하고 있을 수 있으며, 나머지 1종은 재조합 벡터로 형질전환되거나 상기 유전자가 염색체상에 삽입되도록 유전자 조작된 것일 수 있다.In addition, the microorganism can be obtained by converting 2-hydroxyalkanoate into 2-hydroxyalkanoyl-CoA, converting 3-hydroxyalkanoate into 3-hydroxyalkanoyl-CoA, A gene encoding an enzyme that converts alkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- And the other one may be transformed with a recombinant vector or genetically engineered such that the gene is inserted on the chromosome.
예를 들어, 상기 미생물은, 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 포함하는 세포에, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자를 형질전환하여 수득된 것일 수 있다.For example, the microorganism may be a cell comprising a gene encoding a PHA synthase using 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- , 2-hydroxyalkanoate was converted into 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate was converted into 3-hydroxyalkanoyl-CoA, 4-hydroxyalkanoate was converted into 3-hydroxyalkanoyl- May be obtained by transforming a gene encoding an enzyme that converts to 4-hydroxyalkanoyl-CoA.
다른 예로, 상기 미생물은, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자를 포함하는 세포에, 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자를 형질전환하여 수득된 것일 수 있다.As another example, the microorganism can be obtained by converting 2-hydroxyalkanoate into 2-hydroxyalkanoyl-CoA, converting 3-hydroxyalkanoate into 3-hydroxyalkanoyl-CoA, Hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA, and 4-hydroxyalkanoyl-CoA are added to cells containing a gene encoding an enzyme that converts the Roxy alkanoate to 4-hydroxyalkanoyl- It may be one obtained by transforming a gene encoding PHA synthetase using a Nooll-CoA as a substrate.
유전자 재조합 방법으로 상기 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 생산하는 미생물을 제조하거나 상기 미생물을 이용하여 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 생산하는 과정은 다음 단계를 포함할 수 있다.Hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer is produced by a recombinant method or by using the microorganism to produce 4-hydroxybutyrate-3-hydroxybutyrate- The process for producing the hydroxybutyrate terpolymer may comprise the following steps.
우선, 2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자 중 1종 이상을 벡터에 삽입하여 재조합 벡터를 제조하는 단계이다. 위 2종의 유전자는 각각 별도의 벡터에 삽입될 수도 있고, 하나의 벡터에 삽입될 수도 있다.First, 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, and 4-hydroxyalkanoate is converted to 3- A gene encoding an enzyme that converts to 4-hydroxyalkanoyl-CoA, and a PHA using 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- And inserting at least one gene encoding a synthetic enzyme into a vector to prepare a recombinant vector. These two genes may be inserted into separate vectors or inserted into a single vector.
용어, "벡터"는 개체의 세포 내에서 목적 단백질을 코딩하는 유전자 삽입물이 발현되도록 작동가능하게 연결된 필수적인 조절 요소를 포함하는 유전자 작제물을 말하며, 목적 단백질을 코딩하는 핵산 서열을 숙주 세포로 도입되기 위한 수단이 된다. 상기 벡터로는 플라스미드, 바이러스 벡터, 박테리오파지 벡터, 코즈미드 벡터, YAC(Yeast Artificial Chromosome) 벡터 등 다양한 형태의 벡터를 사용할 수 있다. 재조합 벡터는 클로닝 벡터 및 발현 벡터를 포함한다. 클로닝 벡터는 복제기점, 예를 들어 플라스미드, 파지 또는 코스미드의 복제 기점을 포함하며, 다른 DNA 절편이 부착되어 부착된 절편이 복제될 수 있는 레플리콘이다. 발현 벡터는 단백질을 합성하는데 사용되도록 개발되었다.The term "vector" refers to a gene construct comprising an essential regulatory element operably linked to the expression of a gene insert encoding a desired protein in a cell of an individual, wherein the nucleic acid sequence encoding the desired protein is introduced into the host cell . Various vectors such as a plasmid, a virus vector, a bacteriophage vector, a cosmid vector, and a YAC (Yeast Artificial Chromosome) vector may be used as the above-mentioned vector. The recombinant vector includes a cloning vector and an expression vector. A cloning vector is a replicon that includes a replication origin, for example, a replication origin of a plasmid, phage or cosmid, and in which the fragment to which another DNA fragment is attached can be cloned. Expression vectors have been developed to be used to synthesize proteins.
본원에서 벡터는 원핵세포 또는 진핵세포 등 각종 숙주 세포에서 목적하는 효소 유전자를 발현하고 이를 생산하는 기능을 하면 특별히 한정되지 않지만, 벡터내로 삽입되어 전달된 유전자가 숙주세포의 게놈 내로 비가역적으로 융합되어 세포 내에서 유전자 발현이 장기간 안정적으로 지속되도록 하는 벡터가 바람직하다.The vector is not particularly limited insofar as it expresses the desired enzyme gene in various host cells such as prokaryotic cells or eukaryotic cells and is capable of producing it. However, the vector is inserted into the vector and the transferred gene is irreversibly fused into the genome of the host cell A vector that allows gene expression to be stably maintained in the cell for a long period of time is preferable.
이러한 벡터는, 해당 유전자가 선택된 숙주 내에서 발현될 수 있도록 하는 전사 및 해독 발현 조절 서열을 포함한다. 발현 조절 서열로는, 전사를 실시하기 위한 프로모터, 그러한 전사를 조절하기 위한 임의의 오퍼레이터 서열, 적합한 mRNA 리보좀 결합 부위를 코딩하는 서열 및/또는 전사 및 해독의 종결을 조절하는 서열을 포함할 수 있다. 예를 들면, 원핵생물에 적합한 조절 서열은 프로모터, 임의로 오퍼레이터 서열 및/또는 리보좀 결합 부위를 포함할 수 있다. 진핵세포에 적합한 조절 서열은 프로모터, 터미네이터 및/또는 폴리아데닐화 시그날을 포함할 수 있다. 개시 코돈 및 종결 코돈은 일반적으로 목적 단백질을 코딩하는 핵산 서열의 일부로 간주되며, 유전자 작제물이 투여되었을 때 개체에서 작용을 나타내야 하며 코딩 서열과 인프레임(in frame)에 있어야 한다. 벡터의 프로모터는 구성적 또는 유도성일 수 있다. 또한 복제 가능한 발현벡터인 경우 복제 기원을 포함할 수 있다. 그 외에, 인핸서, 목적하는 유전자의 5' 말단 및 3' 말단의 비해독영역, 선별 마커(예컨대, 항생제 내성 마커), 또는 복제가능단위 등을 적절하게 포함할 수도 있다. 벡터는 자가 복제하거나 숙주 게놈 DNA에 통합될 수 있다.Such vectors include transcriptional and detoxification expression control sequences that allow the gene to be expressed in a selected host. Expression control sequences may include promoters for conducting transcription, any operator sequences for regulating such transcription, sequences encoding suitable mRNA ribosome binding sites, and / or sequences that control the termination of transcription and translation . For example, regulatory sequences suitable for prokaryotes may include a promoter, optionally an operator sequence and / or a ribosome binding site. Regulatory sequences suitable for eukaryotic cells may include promoters, terminators and / or polyadenylation signals. The initiation codon and the termination codon are generally considered to be part of the nucleic acid sequence encoding the target protein and should act in the individual when the gene construct is administered and in the coding sequence and in frame. The promoter of the vector may be constitutive or inducible. It may also contain a cloning source if it is a replicable expression vector. In addition, an enhancer, a toxin region at the 5 'end and a 3' end of the gene of interest, a selectable marker (for example, an antibiotic resistance marker), or a replicable unit may suitably be contained. The vector may be self-replicating or integrated into the host genomic DNA.
유용한 발현 조절 서열의 예로는, 아데노바이러스의 초기 및 후기 프로모터들, 원숭이 바이러스 40(SV40), 마우스 유방 종양 바이러스(MMTV) 프로모터, HIV의 긴 말단 반복부(LTR) 프로모터, 몰로니 바이러스, 시토메갈로바이러스(CMV) 프로모터, 엡스타인 바이러스(EBV) 프로모터, 로우스 사코마 바이러스(RSV) 프로모터, RNA 폴리머라제 Ⅱ 프로모터, β-액틴 프로모터, 사람 헤로글로빈 프로모터 및 사람 근육 크레아틴 프로모터, lac 시스템, trp 시스템, TAC 또는 TRC 시스템, T3 및 T7 프로모터들, 파지 람다의 주요 오퍼레이터 및 프로모터 영역, fd 코드 단백질의 조절 영역, 포스포글리세레이트 키나아제 (phosphoglycerate kinase, PGK) 또는 다른 글리콜분해 효소에 대한 프로모터, 포스파타제의 프로모터들, 예를 들어 Pho5, 효모 알파-교배 시스템의 프로모터 및 원핵세포 또는 진핵 세포 또는 이들의 바이러스의 유전자의 발현을 조절하는 것으로 알려진 구성과 유도의 기타 다른 서열 및 이들의 여러 조합을 포함할 수 있다.Examples of useful expression control sequences include early and late promoters of adenovirus, monkey virus 40 (SV40), mouse mammary tumor virus (MMTV) promoter, long terminal repeat (LTR) promoter of HIV, Moloney virus, A lac system, a trp system, a human cytomegalovirus (CMV) promoter, an Epstein-Barr virus (EBV) promoter, a rosacekoma virus (RSV) promoter, an RNA polymerase II promoter, The TAC or TRC system, the T3 and T7 promoters, the major operator and promoter regions of phage lambda, the regulatory region of the fd coding protein, the promoter for phosphoglycerate kinase (PGK) or other glycolytic enzymes, the promoter of phosphatase , Such as Pho5, the promoter and prokaryotic cell of the yeast alpha-mating system, or It may include a cell or a nucleus-known configuration and induce other sequences and these various combinations of the genes that control the expression of these virus.
세포에서 형질전환 유전자의 발현 수준을 높이기 위해서는 목적하는 유전자와 전사 및 해독 발현 조절 서열이 서로 작동가능하도록 연결되어야 한다. 일반적으로, "작동가능하게 연결된"은 연결된 DNA 서열이 접촉하고, 또한 분비 리더의 경우 접촉하고 리딩 프레임 내에 존재하는 것을 의미한다. 예를 들면, 전서열(pre-sequence) 또는 분비 리더(leader)에 대한 DNA가 단백질의 분비에 참여하는 전단백질로서 발현되는 경우 폴리펩타이드에 대한 DNA에 작동가능하게 연결될 수 있고, 프로모터 또는 인핸서가 서열의 전사에 영향을 끼치는 경우 코딩서열에 작동가능하게 연결될 수 있고, 또는 리보좀 결합 부위는 서열의 전사에 영향을 끼치는 경우 코딩 서열에 작동가능하게 연결될 수 있고, 또는 리보좀 결합 부위는 번역을 용이하게 하도록 배치되는 경우 코딩 서열에 작동가능하게 연결될 수 있다. 이들 서열의 연결은 편리한 제한 효소 부위에서 라이게이션(연결)에 의해 수행될 수 있고, 그러한 부위가 존재하지 않는 경우, 통상의 방법에 따른 합성 올리고뉴클레오티드 어댑터(oligonucleotide adaptor) 또는 링커(linker)를 사용하여 수행될 수 있다.In order to increase the expression level of the transgene in the cell, the desired gene and the transcriptional and detoxification expression control sequences should be operatively linked to each other. Generally, "operably linked" means that the linked DNA sequences are in contact and, in the case of a secretory leader, are in contact and present in the reading frame. For example, if the DNA for a pre-sequence or secretory leader is expressed as a whole protein participating in the secretion of the protein, it can be operably linked to the DNA for the polypeptide and the promoter or enhancer Or the ribosome binding site can be operably linked to the coding sequence if it affects the transcription of the sequence, or the ribosome binding site can be operably linked to the coding sequence if it affects the transcription of the sequence, , It can be operably linked to a coding sequence. The linkage of these sequences can be performed by ligation at convenient restriction sites and, if such sites are not present, using a synthetic oligonucleotide adapter or linker according to conventional methods . ≪ / RTI >
당업자는 숙주 세포의 성질, 벡터의 복제 수, 복제 수를 조절할 수 있는 능력 및 당해 벡터에 의해 코딩되는 다른 단백질, 예를 들어 항생제 마커의 발현 등을 고려하여, 본 발명에 적합한 각종 벡터, 발현 조절 서열, 숙주 등을 선정할 수 있다.Those skilled in the art will appreciate that various vectors suitable for the present invention, expression controllability and the like, in consideration of the nature of the host cell, the number of copies of the vector, the ability to regulate the number of copies, and other proteins encoded by the vector, Sequence, and host can be selected.
다음은, 상기 재조합 벡터를 사용해서 미생물을 형질전환시키는 단계이다.Next, the microorganism is transformed using the recombinant vector.
용어, "형질전환"은 DNA를 숙주로 도입하여 DNA가 염색체외 인자로서 또는 염색체 통합완성에 의해 복제가능하게 되는 것을 의미한다. The term "transformation" refers to the introduction of DNA into a host such that the DNA is replicable as an extrachromosomal element or by chromosome integration completion.
본 발명에 따른 재조합 벡터로 형질전환될 수 있는 미생물은 원핵 세포와 진핵 세포 모두를 포함하며, DNA의 도입효율이 높고, 도입된 DNA의 발현효율이 높은 숙주가 통상 사용될 수 있다. 구체 예로, 대장균 (예를 들어, E. coli DH5a, E. coli JM101, E. coli K12, E. coli W3110, E. coli X1776, E. coli B 및 E. coli XL1-Blue)을 포함하는 에스케리키아 속, 슈도모나스 속, 바실러스 속, 스트렙토마이세스 속, 어위니아 속, 세라티아 속, 프로비덴시아 속, 코리네박테리움 속, 렙토스피라 속, 살모넬라 속, 브레비박테리아 속, 하이포모나스 속, 크로모박테리움 속, 노카디아 속, 진균 또는 효모와 같은 주지의 진핵 및 원핵 숙주 등을 예시할 수 있으나, 이에 제한되는 것은 아니다. 적당한 숙주로 형질전환되면, 벡터는 숙주 게놈과 무관하게 복제하고 기능할 수 있거나, 또는 일부 경우에 게놈 그 자체에 통합될 수 있다. The microorganism which can be transformed with the recombinant vector according to the present invention includes both prokaryotic and eukaryotic cells, and a host having high efficiency of introduction of DNA and high efficiency of expression of the introduced DNA can be usually used. Specific examples, E. coli (e.g., E. coli DH5a, E. coli JM101, E. coli K12, E. coli W3110, E. coli X1776, E. coli B and E. coli XL1-Blue), Escherichia spp., Pseudomonas spp., Bacillus spp., Streptomyces spp., Erwinia spp., Serratia spp., Providencia spp., Corynebacterium spp., Leptospira spp., Salmonella spp. But are not limited to, eukaryotic and prokaryotic hosts such as bacteria, hypomonas, chromobacterium, nocadia, fungi or yeast. Once transformed into the appropriate host, the vector may replicate and function independently of the host genome, or, in some cases, integrate into the genome itself.
또한, 본 발명의 목적상, 상기 숙주 세포는 탄소원으로부터 하이드록시아실-CoA를 생합성하는 경로를 가지고 있는 미생물일 수 있다.For the purpose of the present invention, the host cell may be a microorganism having a pathway for biosynthesis of hydroxyacyl-CoA from a carbon source.
형질전환 방법으로는, 당 분야에서 공지된 바와 같이 적합한 표준 기술, 예들 들어, 전기천공법(electroporation), 전기주입법(electroinjection), 미세주입법(microinjection), 인산칼슘공동-침전법(calcium phosphate co-precipitation), 염화캄슘/염화루비듐법, 레트로바이러스 감염(retroviral infection), DEAE-덱스트란(DEAE-dextran), 양이온 리포좀(cationic liposome)법, 폴리에틸렌 글리콜 침전법(polyethylene glycol-mediated uptake), 유전자총(gene gun) 등을 이용할 수 있으나, 이에 제한되는 것은 아니다. 이 때 원형의 벡터를 적절한 제한효소로 절단하여 선형의 벡터 형태로 도입할 수 있다.Transformation methods include, but are not limited to, using appropriate standard techniques such as electroporation, electroinjection, microinjection, calcium phosphate co- precipitation, precipitation, calcium chloride / rubidium, retroviral infection, DEAE-dextran, cationic liposome, polyethylene glycol-mediated uptake, (gene gun), and the like, but the present invention is not limited thereto. At this time, the vector of circular form can be introduced into a linear vector form by cutting with appropriate restriction enzymes.
다음은, 상기 형질전환된 미생물을 배양하여 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 생산하는 단계이다.Next, the transformed microorganism is cultured to produce 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer.
상기 재조합 벡터가 발현되는 형질전환체를 배지에서 배양하여, 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 대량으로 제조, 분리 가능하다. 배지와 배양조건은 형질전환 세포의 종류에 따라 관용되는 것을 적당히 선택하여 이용할 수 있다. 배양 시 세포의 생육과 삼중합체의 대량 생산에 적합하도록 온도, 배지의 pH 및 배양시간 등의 조건들을 적절하게 조절할 수 있다. 상기 배양 방법의 예에는, 회분식, 연속식 및 유가식 배양이 포함되나, 이에 제한되는 것은 아니다.The transformant expressing the recombinant vector can be cultured in a medium to produce and isolate a large amount of 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer. The medium and culture conditions can be suitably selected depending on the kind of transfected cells. The conditions such as the temperature, the pH of the medium and the incubation time can be appropriately adjusted so as to be suitable for cell growth and mass production of the terpolymer at the time of culturing. Examples of such culture methods include, but are not limited to, batch, continuous, and fed-batch cultivation.
일 구현예로, 상기 배양은 2-하이드록시부티레이트, 3-하이드록시부티레이트 및/또는 4-하이드록시부티레이트를 포함하는 배지에서 수행되는 것일 수 있다. 또한, 글루코즈 등의 탄소원으로부터 2-하이드록시부티레이트, 3-하이드록시부티레이트 및 4-하이드록시부티레이트를 생합성 할 수 있는 미생물이라면, 2-하이드록시부티레이트, 3-하이드록시부티레이트 및/또는 4-하이드록시부티레이트 별도로 첨가하지 않아도 상기 공중합체를 제조할 수 있다.In one embodiment, the culture may be performed in a medium comprising 2-hydroxybutyrate, 3-hydroxybutyrate and / or 4-hydroxybutyrate. Also, in the case of a microorganism capable of biosynthesizing 2-hydroxybutyrate, 3-hydroxybutyrate and 4-hydroxybutyrate from a carbon source such as glucose, 2-hydroxybutyrate, 3-hydroxybutyrate and / The copolymer can be prepared without adding the butyrate separately.
이 외에, 배양에 사용되는 배지는 특정한 균주의 요구조건을 적절하게 만족시켜야 한다. 상기 배지는 다양한 탄소원, 질소원, 인원 및 미량원소 성분을 포함할 수 있다. 배지 내 탄소원으로는 글루코즈, 사카로즈, 락토즈, 프락토즈, 말토즈, 전분, 셀룰로즈와 같은 당 및 탄수화물, 대두유, 해바라기유, 피마자유, 코코넛유 등과 같은 오일 및 지방, 팔미트산, 스테아린산, 리놀레산과 같은 지방산, 글리세롤, 에탄올과 같은 알코올, 아세트산과 같은 유기산을 예시할 수 있으나, 이에 제한되는 것은 아니다. 이들 물질은 개별적으로 또는 혼합물로서 사용될 수 있다. 배지 내 질소원으로는 펩톤, 효모 추출물, 육즙, 맥아 추출물, 옥수수 침지액, 대두밀 및 요소 또는 무기 화합물, 예를 들면 황산암모늄, 염화암모늄, 인산암모늄, 탄산암모늄 및 질산암모늄을 예시할 수 있으나, 이에 제한되는 것은 아니다. 질소원 또한 개별적으로 또는 혼합물로서 사용할 수 있다. 배지 내 인원으로는 인산이수소칼륨 또는 인산수소이칼륨 또는 상응하는 나트륨-함유 염을 예시할 수 있으나, 이에 제한되는 것은 아니다. 또한, 배양 배지는 성장에 필요한 황산마그네슘 또는 황산철과 같은 금속염을 포함하거나, 아미노산 및 비타민과 같은 필수 성장 물질을 포함할 수 있으나, 이에 제한되는 것은 아니다. 상기된 원료들은 배양 과정에서 배양물에 적절한 방식에 의해 회분식으로 또는 연속식으로 첨가될 수 있다.In addition to this, the medium used for cultivation should suitably satisfy the requirements of the specific strains. The medium may include various carbon sources, nitrogen sources, phosphorus, and trace element components. Carbon sources in the medium include sugars and carbohydrates such as glucose, saccharose, lactose, fructose, maltose, starch and cellulose, oils and fats such as soybean oil, sunflower oil, castor oil and coconut oil, palmitic acid, Fatty acids such as linoleic acid, glycerol, alcohols such as ethanol, and organic acids such as acetic acid. These materials may be used individually or as a mixture. Examples of the nitrogen source in the medium include peptone, yeast extract, juice, malt extract, corn steep liquor, soybean wheat and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, But is not limited thereto. The nitrogen source may also be used individually or as a mixture. Examples of the materials in the medium include, but are not limited to, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium-containing salts. In addition, the culture medium may include metal salts such as magnesium sulfate or iron sulfate necessary for growth, or may include essential growth materials such as amino acids and vitamins, but is not limited thereto. The above-mentioned raw materials can be added to the culture in a batch manner or in a continuous manner by an appropriate method.
또한, 필요에 따라, 수산화나트륨, 수산화칼륨, 암모니아와 같은 기초 화합물 또는 인산 또는 황산과 같은 산 화합물을 적절한 방식으로 사용하여 배양물의 pH를 조절할 수 있다. 또한, 지방산 폴리글리콜 에스테르와 같은 소포제를 사용하여 기포 생성을 억제할 수 있다. 호기 상태를 유지하기 위해 배양물 내로 산소 또는 산소-함유 기체 (예, 공기)를 주입할 수 있으며, 배양물의 온도는 보통 20℃ 내지 45℃, 바람직하게는 25℃ 내지 40℃ 일 수 있다. 배양은 원하는 삼중합체의 생산량이 최대로 얻어질 때까지 계속될 수 있다.In addition, if necessary, the pH of the culture can be adjusted by using a basic compound such as sodium hydroxide, potassium hydroxide, ammonia or an acid compound such as phosphoric acid or sulfuric acid in a suitable manner. In addition, bubble formation can be suppressed by using a defoaming agent such as a fatty acid polyglycol ester. Oxygen or oxygen-containing gas (e.g., air) may be injected into the culture to maintain aerobic conditions, and the temperature of the culture may be usually 20 ° C to 45 ° C, preferably 25 ° C to 40 ° C. The culture can continue until the desired yield of the desired terpolymer is obtained.
다음은, 상기 생산된 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 회수하는 단계이다.The next step is to recover the produced 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer.
재조합 미생물로부터 생산된 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체는, 당업계에 널리 알려져 있는 방법으로 세포 또는 배양 배지로부터 분리해낼 수 있다. 삼중합체의 회수 방법의 예로서, 원심분리, 초음파파쇄, 여과, 이온교환 크로마토그래피, 고성능 액체 크로마토그래피(high performance liquid chromatography: HPLC), 가스 크로마토그래피(gas chromatography: GC) 등의 방법이 있으나, 이들 예에 한정되는 것은 아니다.The 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer produced from the recombinant microorganism can be isolated from the cell or culture medium in a manner well known in the art. Examples of the method for recovering the terpolymer include centrifugal separation, ultrasonic disruption, filtration, ion exchange chromatography, high performance liquid chromatography (HPLC), and gas chromatography (GC) The present invention is not limited to these examples.
본 발명은 4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 제공하며, 이는 생분해성 및 생체적합성이 있는 바이오플라스틱의 원료로서, 전자, 자동차, 식품, 농업 및 의료 분야 등에 폭넓게 활용될 수 있다.The present invention provides a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units, which is a raw material for biodegradable and biocompatible bioplastics, Food, agricultural and medical fields.
도 1은 pPs619C1310-CpPCT540 벡터의 제작 과정 및 개열 지도를 나타낸 것이다.
도 2는 pPs619C1249.18H-CPPCT540 벡터의 개열 지도를 나타낸 것이다.
도 3은 재조합 미생물로부터 생산된 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체를 가스크로마토그래피로 분석한 결과를 나타낸다.Figure 1 shows the production process and cleavage map of the vector pPs619C1310-CpPCT540.
Fig. 2 shows a cleavage map of the vector pPs619C1249.18H-CPPCT540.
Fig. 3 shows the result of analysis of the 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer produced from the recombinant microorganism by gas chromatography.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.
실시예Example 1. 4- 1. 4- 하이드록시부티레이트Hydroxybutyrate -3--3- 하이드록시부티레이트Hydroxybutyrate -2--2- 하이드록시부티레이트Hydroxybutyrate 삼중합체의 제조용 재조합 벡터의 제조 Preparation of recombinant vector for preparation of trimer
1-1. 1-1. pPs619C1310pPs619C1310 -- CPPCT540CPPCT540 재조합 벡터의 제조 Preparation of recombinant vector
프로피오닐-CoA 트랜스퍼라아제 유전자(pct)는 클로스트리듐 프로피오니쿰(Clostridium propionicum) 유래의 프로피오닐-CoA 트랜스퍼라아제(CP-PCT)의 변이체를 사용하였고, PHA 합성효소 유전자는 슈도모나스 속 MBEL 6-19 (KCTC 11027BP) 유래의 PHA 합성효소의 변이체를 사용하였다. 이 때 사용된 벡터는 pBluescript II (Stratagene Co., USA)이다.The propionyl-CoA transferase gene (pct) used a mutant of propionyl-CoA transferase (CP-PCT) derived from Clostridium propionicum, and the PHA synthase gene was Pseudomonas sp. MBEL 6-19 (KCTC 11027BP) were used. The vector used was pBluescript II (Stratagene Co., USA).
우선, PHA 합성효소(phaC1Ps6 -19) 유전자를 분리하기 위하여, 슈도모나스 속 MBEL 6-19 (KCTC 11027BP)의 전체 DNA를 추출하고, phaC1Ps6 -19 유전자 서열(서열번호 3)에 기반하여, 프라이머[5'-GAG AGA CAA TCA AAT CAT GAG TAA CAA GAG TAA CG-3'(서열번호 5), 5'-CAC TCA TGC AAG CGT CAC CGT TCG TGC ACG TAC-3'(서열번호 6)]를 제작하고, 상기 추출한 전체 DNA를 주형으로 하여, PCR을 수행하였다. 얻어진 PCR 산물을 전기영동하여, phaC1Ps6 -19 유전자에 해당하는 1.7 kb 크기의 유전자 절편을 확인하고, phaC1Ps6 -19 유전자를 수득하였다.First, PHA synthase (phaC1 Ps6 -19) in order to separate the gene, the total DNA extracted of Pseudomonas species MBEL 6-19 (KCTC 11027BP) and, based on the phaC1 Ps6 -19 gene sequence (SEQ ID NO: 3), primer (5'-CAG TCA TGC AAG CGT CAC CGT TCG TGC ACG TAC-3 '(SEQ ID NO: 6)] And PCR was performed using the extracted whole DNA as a template. The resulting PCR products by electrophoresis, it was confirmed that a gene fragment of 1.7 kb size, corresponding to the phaC1 Ps6 -19 gene, and to obtain a phaC1 Ps6 -19 gene.
phaC1Ps6 -19 합성효소를 발현시키기 위하여, pSYL105 벡터(Lee et al ., Biotech. Bioeng., 1994, 44:1337-1347)에서 Ralstonia eutropha H16 유래의 PHB 생산 오페론이 함유된 DNA 절편을 BamHI/EcoRI으로 절단하여, pBluescript II (Stratagene Co., USA)의 BamHI/EcoRI 인식부위에 삽입함으로써 pReCAB 재조합 벡터를 제조하였다. pReCAB 벡터는 PHA 합성효소(phaCRE)와 단량체 공급효소(phaARE 및 phaBRE)가 PHB 오페론 프로모터에 의해 항시적으로 발현된다. BstBI/SbfI 인식 부위가 각각 양끝에 하나씩만 포함된 phaC1Ps6 -19 합성효소 유전자 절편을 만들기 위해 우선 내재하고 있는 BstBI 위치를 SDM(site directed mutagenesis) 방법으로 아미노산의 변환 없이 제거하였고, BstBI/SbfI 인식부위를 첨가하기 위해 프라이머[5'- atg ccc gga gcc ggt tcg aa -3'(서열번호 7), 5'- CGT TAC TCT TGT TAC TCA TGA TTT GAT TGT CTC TC -3'(서열번호 8), 5'- GAG AGA CAA TCA AAT CAT GAG TAA CAA GAG TAA CG -3' (서열번호 9), 5- CAC TCA TGC AAG CGT CAC CGT TCG TGC ACG TAC -3'(서열번호 10), 5'- GTA CGT GCA CGA ACG GTG ACG CTT GCA TGA GTG -3'(서열번호 11), 5'- aac ggg agg gaa cct gca gg -3'(서열번호 12)]를 이용하여 오버랩핑 PCR을 수행하였다. pReCAB 벡터를 BstBI/SbfI으로 절단하여 R. eutropha H16 PHA 합성효소 (phaCRE)를 제거한 다음, 상기에서 수득한 phaC1Ps6 -19 유전자를 BstBI/SbfI 인식부위에 삽입함으로써 pPs619C1-ReAB 재조합 벡터를 제조하였다. phaC1 Ps6 to -19 expressing the synthase, pSYL105 vector (Lee et al . , Biotech. Bioeng ., 1994, 44: 1337-1347) in Ralstonia eutropha A pReCAB recombinant vector was prepared by digesting a DNA fragment containing the PHB-producing operon derived from H16 with BamHI / EcoRI and inserting it into the BamHI / EcoRI recognition site of pBluescript II (Stratagene Co., USA). The pReCAB vector contains the PHA synthase (phaC RE ) and the monomeric donor enzyme (phaA RE And phaB RE ) are constantly expressed by the PHB operon promoter. BstBI / SbfI recognition site was removed BstBI each position and inherent priority to make phaC1 Ps6 -19 synthase gene fragments, one containing only the ends without changing the amino acid SDM (site directed mutagenesis) methods, BstBI / SbfI recognition (SEQ ID NO: 7), 5'-CGT TAC TCT TGT TAC TCA TGA TTT GAT TGT CTC TC -3 '(SEQ ID NO: 8), 5'- 5'-GAG AGA CAA TCA AAT CAT GAG TAA CAA GAG TAA CG -3 '(SEQ ID NO: 9), 5-CAC TCA TGC AAG CGT CAC CGT TCG TGC ACG TAC -3' CGT GCA CGA ACG GTG ACG CTT GCA TGA GTG -3 '(SEQ ID NO: 11), 5'-aac ggg agg gaa cct gca gg -3' (SEQ ID NO: 12)]. The pReCAB vector was digested with BstBI / SbfI to obtain R. eutropha H16, remove the PHA synthase (phaC RE) and then by inserting the phaC1 Ps6 -19 gene obtained above in the BstBI / SbfI recognition site to prepare a recombinant vector pPs619C1-ReAB.
SCL(short chain length) 활성에 영향을 미치는 아미노산 위치 3 곳을 아미노산 서열 배열분석을 통해 찾았고, 프라이머[5'- CTG ACC TTG CTG GTG ACC GTG CTT GAT ACC ACC- 3'(서열번호 13), 5- GGT GGT ATC AAG CAC GGT CAC CAG CAA GGT CAG- 3'(서열번호 14), 5'- CGA GCA GCG GGC ATA TC A TGA GCA TCC TGA ACC CGC- 3'(서열번호 15), 5'- GCG GGT TCA GGA TGC TCA TGA TAT GCC CGC TGC TCG- 3'(서열번호 16), 5'- atc aac ctc atg acc gat gcg atg gcg ccg acc- 3'(서열번호 17), 5'- ggt cgg cgc cat cgc atc ggt cat gag gtt gat- 3'(서열번호 18)]를 사용한 SDM 방법을 이용하여, E130D, S325T, Q481M 을 포함하는 phaC1Ps6 -19 합성효소 변이체인 phaC1Ps6 -19300을 함유한 pPs619C1300-ReAB 를 제조하였다.Three amino acid positions that affect SCL (short chain length) activity were found through amino acid sequence analysis. The primers [5'-CTG ACC TTG CTG GTG ACC GTG CTT GAT ACC ACC- 3 ' - GGT GGT ATC AAG CAC GGT CAC CAG CAA GGT CAG- 3 '(SEQ ID NO: 14), 5'-CGA GCA GCG GGC ATA TC A TGA GCA TCC TGA ACC CGC- GGT TCA GGA TGC TCA TGA TAT GCC CGC TGC TCG- 3 '(SEQ ID NO: 16), 5'-atc aac ctc atg acc gat gcg atg gcg ccg acc- 3' (SEQ ID NO: 17), 5'- ggt cgg cgc cat cgc atc ggt cat gag gtt gat- 3 '( SEQ ID NO: 18) for using the SDM method using, E130D, S325T, phaC1 Ps6 -19 Q481M containing a pPs619C1300- containing synthase mutant of phaC1 Ps6 -19 300 ReAB was prepared.
여기에 프로피오닐-CoA 트랜스퍼라아제가 같이 발현되는 오페론 형태의 항시적 발현되는 시스템을 구축하기 위하여 클로스트리듐 프로피오니쿰(Clostridium propionicum) 유래의 프로피오닐-CoA 트랜스퍼라아제 (CP-PCT)를 사용하였다. CP-PCT는 클로스트리듐 프로피오니쿰의 염색체 DNA를 프라이머[5'-GGAATTCATGAGAAAGGTTCCCATTATTACCGCAGATGA-3'(서열번호 19), 5'-gc tctaga tta gga ctt cat ttc ctt cag acc cat taa gcc ttc tg-3'(서열번호 20)]를 이용하여 PCR하여 얻어진 단편을 사용하였다. 이 때, 원래 야생형 CP-PCT에 존재하는 NdeI site를 cloning의 용이성을 위해 SDM 방법을 이용하여 제거하였고, SbfI/NdeI 인식부위를 첨가하기 위해 프라이머[5'-agg cct gca ggc gga taa caa ttt cac aca gg- 3'(서열번호 21), 5'-gcc cat atg tct aga tta gga ctt cat ttc c- 3'(서열번호 22)]를 이용하여 오버랩핑 PCR을 수행하였다. pPs619C1300-ReAB 벡터를 SbfI/NdeI으로 절단하여 Ralstonia eutrophus H16 유래의 단량체 공급효소 (phaARE 및 phaBRE)를 제거한 다음, 상기 PCR 클로닝한 CP-PCT 유전자를 SbfI/NdeI 인식 부위에 삽입함으로써 pPs619C1300-CPPCT 재조합 벡터를 제조하였다.In order to construct an always expressed system of the operon type in which the propionyl-CoA transferase is expressed in the same manner, propionyl-CoA transferase (CP-PCT) derived from Clostridium propionicum Respectively. CP-PCT was constructed by amplifying the chromosomal DNA of Clostridium propionikum with the primers [5'-GGAATTCATGAGAAAGGTTCCCATTATTACCGCAGATGA-3 '(SEQ ID NO: 19), 5'-gc tctaga tta gga ctt cat ttc ctt cag acc cat taa gcc ttc tg- (SEQ ID NO: 20)] was used. At this time, the NdeI site existing in the original wild-type CP-PCT was removed by SDM method for ease of cloning, and the primer [5'-agg cct gca ggc gga taa caa ttt cac 3 '(SEQ ID NO: 21), 5'-gcc catgatte agatta gga cttcat ttc c-3' (SEQ ID NO: 22). The pPs619C1300-ReAB vector was digested with SbfI / NdeI to obtain Ralstonia eutrophus The H16-derived monomer-supplying enzyme (phaA RE And phaB RE ), and then the PCR-cloned CP-PCT gene was inserted into the SbfI / NdeI recognition site to prepare a pPs619C1300-CPPCT recombinant vector.
다음으로, CP-PCT 유전자에 무작위적 돌연변이(random mutagenesis)를 도입하기 위해 상기에서 제작된 pPs619C1300-CPPCT을 주형으로 하고, 프라이머[5'-CGCCGGCAGGCCTGCAGG-3'(서열번호 23), 5'-GGCAGGTCAGCCCATATGTC-3'(서열번호 24)]를 이용하여 Mn2 +이 첨가되고 dNTPs의 농도 차이가 존재하는 조건에서 Error-prone PCR을 실시하였다. 그 후, 무작위적 돌연변이가 포함된 PCR 단편을 증폭하기 위해 상기 프라이머를 이용하여 일반 조건에서 PCR하였다. pPs619C1300-CPPCT 벡터를 SbfI/NdeI으로 절단하여 야생형 CP-PCT 를 제거한 후, 상기 증폭된 돌연변이 PCR 단편을 SbfI/NdeI 인식부위에 삽입시킨 ligation mixture를 만들어 E. coli JM109에 도입하여 ~105정도 규모의 CP-PCT 라이브러리를 제작하였다. 상기 제작된 CP-PCT 라이브러리는 고분자 검출배지(LB agar, glucose 20g/L, 3HB 1g/L, Nile red 0.5μg/ml)에서 3일간 생육시킨 후 고분자 생성 여부를 확인하는 스크리닝 작업을 수행하여 ~80여 개체의 후보를 1차 선정하였다. 이들 후보를 고분자가 생성되는 조건에서 4일간 액체 배양(LB agar, glucose 20g/L, 3HB 1g/L, ampicillin 100mg/L, 37℃)하였고, FACS(Florescence Activated Cell Sorting) 분석을 통하여 2 개체, 즉 CP-PCT Variant 512 (핵산치환 A1200G 포함) 및 CP-PCT Variant 522 (핵산치환 T78C, T669C, A1125G, T1158C 포함)를 선정하였다. 상기 1차 선별된 돌연변이체들(CP-PCT Variant 512, CP-PCT Variant 522)을 기본으로 다시 상기 Error-prone PCR의 방법으로 무작위적 돌연변이를 수행하여 다양한 CP-PCT 변이체들을 얻을 수 있었고, 그 중 CP-PCT Variant 540 (Val193Ala 및 침묵돌연변이 T78C, T669C, A1125G, T1158C 포함)를 2차 선별하여 pPs619C1300-CPPCT540 벡터를 제조하였다.Next, primers [5'-CGCCGGCAGGCCTGCAGG-3 '(SEQ ID NO: 23), 5'-GGCAGGTCAGCCCATATGTC (SEQ ID NO: 23)) were prepared using the above prepared pPs619C1300-CPPCT as a template to introduce a random mutagenesis into the CP- -3 '(SEQ ID NO: 24) was used to perform error-prone PCR under the condition that Mn 2 + was added and the concentration difference of dNTPs existed. Thereafter, PCR was carried out under normal conditions using the above primers to amplify a PCR fragment containing a random mutation. pPs619C1300-CPPCT then by cutting the vector with SbfI / NdeI to remove wild-type CPPCT, to create the ligation mixture was inserted into the amplified PCR fragments to the mutant SbfI / NdeI recognition site introduced in E. coli JM109 ~ 10 5 degree scale Of CP-PCT library. The prepared CP-PCT library was grown in a polymer detection medium (LB agar, glucose 20 g / L, 3HB 1 g / L, Nile red 0.5 μg / ml) for 3 days, Candidates of 80 individuals were selected first. These candidates were subjected to liquid culture (LB agar, glucose 20g / L, 3HB 1g / L, ampicillin 100mg / L, 37 ℃) for 4 days under the conditions of polymer production and analyzed by FACS (Florescence Activated Cell Sorting) CP-PCT Variant 512 (including nucleic acid substitution A1200G) and CP-PCT Variant 522 (including nucleic acid substitutions T78C, T669C, A1125G and T1158C) were selected. Various CP-PCT variants were obtained by random mutagenesis using the above-mentioned error-prone PCR method based on the above-mentioned primary mutants (CP-PCT Variant 512 and CP-PCT Variant 522) The CP-PCT Variant 540 (including Val193Ala and the silent mutants T78C, T669C, A1125G, and T1158C) was secondly selected to prepare the pPs619C1300-CPPCT540 vector.
또한, 상기 제조한 phaC1Ps6 -19 합성효소 변이체(phaC1Ps6-19300)를 기초로 하여 프라이머[5'-gaa ttc gtg ctg tcg agc cgc ggg cat atc- 3' (서열번호 25), 5'-gat atg ccc gcg gct cga cag cac gaa ttc- 3'(서열번호 26), 5'-ggg cat atc aag agc atc ctg aac ccg c-3'(서열번호 27), 5'-g cgg gtt cag gat gct ctt gat atg ccc-3'(서열번호 28)]를 사용한 SDM 방법을 이용하여 E130D, S477F 및 Q481K 이 변이된 아미노산 서열을 가진 슈도모나스 속 MBEL 6-19 유래 PHA 합성효소 변이체(phaC1Ps6 -19310) 를 함유한 pPs619C1310-CPPCT540 벡터를 제조하였다(도 1).Further, the above prepared phaC1 Ps6 -19 synthase variant (phaC1 Ps6-19 300) primers [5'-gaa ttc gtg ctg tcg agc cgc ggg cat atc- 3 '( SEQ ID NO: 25) on the basis of, 5'- gat at c cc gcg gct cg cag cac gaa ttc- 3 '(SEQ ID NO: 26), 5'-ggg cat atc aag agc atc ctg aac ccg c-3' (phaC1 Ps6 -19 310) derived from Pseudomonas sp. MBEL 6-19 having the amino acid sequence of E130D, S477F and Q481K mutated using the SDM method using the cct gat atg ccc-3 '(SEQ ID NO: 28) (PPs619C1310-CPPCT540 vector) (Fig. 1).
1-2. 1-2. pPs619C1249pPs619C1249 .18H-.18H- CPPCT540CPPCT540 재조합 벡터의 제조 Preparation of recombinant vector
상기 1-1 에서 제조한 pPs619C1310-CPPCT540 벡터를 주형으로 하여 프라이머[5'-ATGCCCGGAGCCGGTTCGAA-3'(서열번호 29) 및 5'-GAAATTGTTATCCGCCTGCAGG-3'(서열번호 30)]를 사용하여 error-prone PCR을 수행하였다. error-prone PCR을 수행한 후 돌연변이가 포함된 PCR 단편을 증폭하기 위해 상기 프라이머를 이용하여 다시 PCR 한 후 증폭된 돌연변이들을 pPs619C1310-CPPCT540 벡터의 BstBI/SbfI 위치에 삽입하여 변이체들에 대한 라이브러리를 제작하였다. 제작된 변이체 라이브러리를 E.coli XL-1Blue에 형질전환 시키고, 이를 PHB 검출배지(LB agar, glucose 20g/L, Nile red 0.5μg/ml)에서 3일 동안 배양했다. 배양 후 스크리닝 과정을 통해 최종 선별된 변이체는 L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K 및 A527S이 변이된 아미노산 서열을 가진 pPs619C1249.18H 이었다. 이렇게 하여 재조합 벡터 pPs619C1249.18H-CPPCT540 벡터를 제조하였다(도 2).PCR was performed using the primers [5'-ATGCCCGGAGCCGGTTCGAA-3 '(SEQ ID NO: 29) and 5'-GAAATTGTTATCCGCCTGCAGG-3' (SEQ ID NO: 30)] using the pPs619C1310-CPPCT540 vector prepared in 1-1 above as a template. Respectively. After performing error-prone PCR, PCR was performed again using the above primers to amplify the PCR fragment containing the mutation, and the amplified mutants were inserted into the BstBI / SbfI site of the pPs619C1310-CPPCT540 vector to construct a library of mutants Respectively. The prepared mutant library was transformed into E. coli XL-1 Blue and cultured in PHB detection medium (LB agar, glucose 20 g / L, Nile red 0.5 μg / ml) for 3 days. The final screened mutants through screening after incubation were pPs619C1249.18H with the mutated amino acid sequence of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K and A527S. Thus, the recombinant vector pPs619C1249.18H-CPPCT540 vector was prepared (Fig. 2).
실시예Example 2. 2. ldhAldhA 유전자가 The gene 넉아웃(knock-out)된Knock-out E. E. colicoli XL1- XL1- BlueBlue 변이체Mutant 제작 making
Escherichia coli XL1-Blue (Stratagene, USA)를 바탕으로 하여 락테이트가 포함되지 않는 중합체를 생산하기 위하여 대장균의 대사과정 중 락테이트 생산에 관여하는 D-락테이트디하이드로게나제(LdhA)를 genomic DNA에서 knouk-out 시켰다. 유전자의 결실은 업계에 잘 알려져 있는 red-recombination 방법을 이용하였다. ldhA를 결실시키기 위해 사용된 올리고머는 서열번호 31(5'-atcagcgtacccgtgatgctaacttctctctggaaggtctgaccggctttaattaaccctcactaaagggcg-3') 및 서열번호 32 (5'-atcagcgtacccgtgatgctaacttctctctggaaggtctgaccggctttaattaaccctcactaaagggcg-3')의 염기서열로 합성하였다.In order to produce a lactate-free polymer based on Escherichia coli XL1-Blue (Stratagene, USA), D-lactate dehydrogenase (LdhA) involved in lactate production during the metabolism of E. coli was transformed into genomic DNA Knocked out. Genetic deletions were made using the red-recombination method well known in the art. The oligomer used to delete ldhA was synthesized by the nucleotide sequence of SEQ ID NO: 31 (5'-atcagcgtacccgtgatgctaacttctctctggaaggtctgaccggctttaattaaccctcactaaagggcg-3 ') and SEQ ID NO: 32 (5'-atcagcgtacccgtgatgctaacttctctctggaaggtctgaccggctttaattaaccctcactaaagggcg-3').
실시예Example 3. 4- 3. 4- 하이드록시부티레이트Hydroxybutyrate -3--3- 하이드록시부티레이트Hydroxybutyrate -2--2- 하이드록시부티레이트Hydroxybutyrate 삼중합체의Of the terpolymer 제조 Produce
실시예 1에서 제작된 재조합 벡터를 실시예 2에서 제작된 ldhA가 knock-out 된 E.coli XL1-BlueΔldhA 에 전기천공법(electroporation)을 이용하여 형질전환 시킴으로써 재조합 E.coli XL1-BlueΔldhA 를 제작하였다. 이를 이용하여 상기의 삼중합체를 제조하기 위해 플라스크 배양을 수행하였다. 먼저 전 배양(seed culture)을 위해 상기 재조합 대장균을 100mg/L 앰피실린(ampicillin)과 20mg/L 카나마이신이 함유되어 있는 3 mL의 LB 배지[BactoTM Triptone(BD) 10g/L, BactoTM yeast extract(BD) 5g/L, NaCL(amresco) 10g/L]에서 12시간 배양하였다. 본 배양을 위해, 전 배양액 1ml를 1g/L 의 4-하이드록시부티레이트(4-HB), 1g/L 의 3-하이드록시부티레이트(3-HB), 1g/L의 2-하이드록시부티레이트(2-HB), 100mg/L의 앰피실린, 20mg/L 카나마이신, 10mg/L의 thiamine이 추가로 함유된 100ml MR 배지(1L 당 Glucose 10g, KH2PO4 6.67g, (NH4)2HPO4 4g, MgSO4·7H2O 0.8g, citric acid 0.8g, 및 trace metal solution 5mL; 여기에서, Trace metal solution은 1L 당 5M HCl 5mL, FeSO4?7H2O 10g, CaCl2 2g, ZnSO4?7H2O 2.2g, MnSO4·4H2O 0.5g, CuSO4·5H2O 1g, (NH4)6Mo7O2·4H2O 0.1g, 및 Na2B4O2·10H2O 0.02g)에 접종하여 30℃에서 3일간 250 rpm 으로 교반하며 배양하였다.The recombinant vector prepared in Example 1 was transformed into E. coli XL1-BlueΔldhA knock-out of ldhA prepared in Example 2 using electroporation to produce recombinant E. coli XL1-BlueΔldhA . Flask culture was carried out to prepare the above terpolymer. First, for the seed culture, the recombinant E. coli was inoculated into 3 mL of LB medium [Bacto ™ Triptone (BD) 10 g / L, Bacto ™ yeast extract (BD) containing 100 mg / L ampicillin and 20 mg / L kanamycin (BD) 5 g / L, NaCL (amresco) 10 g / L] for 12 hours. For this cultivation, 1 ml of the preculture was added to 1 g / L 4-hydroxybutyrate (4-HB), 1 g / L 3-hydroxybutyrate (3-HB), 1 g / L 2-hydroxybutyrate (10 g Glucose per liter, 6.67 g KH 2 PO 4 , 4 g NH 4 ) 2HPO 4 , 10 g / L thiamine, 20 mg / L kanamycin and 10 mg / L thiamine, MgSO 4 · 7H 2 O 0.8g, citric acid 0.8g, and trace metal solution 5mL;?? here, Trace metal solution is 5M HCl 5mL, FeSO 4 per 1L 7H 2 O 10g, CaCl 2 2g,
상기 배양액을 4℃, 4000 rpm에서 10분간 원심분리하여 균체를 회수하고 충분한 양의 증류수로 2회 씻어준 후 80℃ 에서 12시간 건조하였다. 제거된 균체를 정량한 후 100℃에서 클로로포름을 용매로 사용하여 황산 촉매 하에서 메탄올과 반응시켜 주었다. 이를 상온에서 클로로포름의 절반에 해당하는 부피의 증류수를 첨가하여 혼합한 후 두 개의 층으로 분리될 때까지 정치시켰다. 두 개의 층 중에서 메틸화된 고분자의 단량체들이 녹아 있는 클로로포름층을 채취하여 가스크로마토그래피(GC)로 고분자의 성분을 분석하였다. 내부 표준물질로는 벤조에이트(benzoate)를 사용하였다. 이 때 사용된 GC 분석조건은 하기의 표 1과 같다.The culture was centrifuged at 4,000 rpm for 10 minutes at 4 ° C to recover the cells, washed twice with a sufficient amount of distilled water, and dried at 80 ° C for 12 hours. The microbial cells were quantified and reacted with methanol under a sulfuric acid catalyst using chloroform as a solvent at 100 ° C. The mixture was added at room temperature with distilled water of half the volume of chloroform, mixed and allowed to stand until separated into two layers. The chloroform layer in which the monomers of the methylated polymer were dissolved was collected from the two layers, and the components of the polymer were analyzed by gas chromatography (GC). As the internal reference material, benzoate was used. The GC analysis conditions used at this time are shown in Table 1 below.
GC 분석결과는 표 2와 도 3에 나타낸 바와 같이, 재조합 대장균에 의해 4-하이드록시부티레이트-3-하이드록시부티레이트-2-하이드록시부티레이트 삼중합체가 생성되었음을 확인할 수 있었다.As a result of GC analysis, it was confirmed that 4-hydroxybutyrate-3-hydroxybutyrate-2-hydroxybutyrate terpolymer was produced by recombinant E. coli as shown in Table 2 and FIG.
<110> LG CHEM, LTD. <120> Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same <130> DPP20147706KR <160> 32 <170> KopatentIn 1.71 <210> 1 <211> 1575 <212> DNA <213> Clostridium propionicum <220> <221> gene <222> (1)..(1575) <223> popionyl-CoA transferase <400> 1 atgagaaagg ttcccattat taccgcagat gaggctgcaa agcttattaa agacggtgat 60 acagttacaa caagtggttt cgttggaaat gcaatccctg aggctcttga tagagctgta 120 gaaaaaagat tcttagaaac aggcgaaccc aaaaacatta cctatgttta ttgtggttct 180 caaggtaaca gagacggaag aggtgctgag cactttgctc atgaaggcct tttaaaacgt 240 tacatcgctg gtcactgggc tacagttcct gctttgggta aaatggctat ggaaaataaa 300 atggaagcat ataatgtatc tcagggtgca ttgtgtcatt tgttccgtga tatagcttct 360 cataagccag gcgtatttac aaaggtaggt atcggtactt tcattgaccc cagaaatggc 420 ggcggtaaag taaatgatat taccaaagaa gatattgttg aattggtaga gattaagggt 480 caggaatatt tattctaccc tgcttttcct attcatgtag ctcttattcg tggtacttac 540 gctgatgaaa gcggaaatat cacatttgag aaagaagttg ctcctctgga aggaacttca 600 gtatgccagg ctgttaaaaa cagtggcggt atcgttgtag ttcaggttga aagagtagta 660 aaagctggta ctcttgaccc tcgtcatgta aaagttccag gaatttatgt tgactatgtt 720 gttgttgctg acccagaaga tcatcagcaa tctttagatt gtgaatatga tcctgcatta 780 tcaggcgagc atagaagacc tgaagttgtt ggagaaccac ttcctttgag tgcaaagaaa 840 gttattggtc gtcgtggtgc cattgaatta gaaaaagatg ttgctgtaaa tttaggtgtt 900 ggtgcgcctg aatatgtagc aagtgttgct gatgaagaag gtatcgttga ttttatgact 960 ttaactgctg aaagtggtgc tattggtggt gttcctgctg gtggcgttcg ctttggtgct 1020 tcttataatg cggatgcatt gatcgatcaa ggttatcaat tcgattacta tgatggcggc 1080 ggcttagacc tttgctattt aggcttagct gaatgcgatg aaaaaggcaa tatcaacgtt 1140 tcaagatttg gccctcgtat cgctggttgt ggtggtttca tcaacattac acagaataca 1200 cctaaggtat tcttctgtgg tactttcaca gcaggtggct taaaggttaa aattgaagat 1260 ggcaaggtta ttattgttca agaaggcaag cagaaaaaat tcttgaaagc tgttgagcag 1320 attacattca atggtgacgt tgcacttgct aataagcaac aagtaactta tattacagaa 1380 agatgcgtat tccttttgaa ggaagatggt ttgcacttat ctgaaattgc acctggtatt 1440 gatttgcaga cacagattct tgacgttatg gattttgcac ctattattga cagagatgca 1500 aacggccaaa tcaaattgat ggacgctgct ttgtttgcag aaggcttaat gggtctgaag 1560 gaaatgaagt cctaa 1575 <210> 2 <211> 524 <212> PRT <213> Clostridium propionicum <220> <221> PEPTIDE <222> (1)..(524) <223> propionyl-CoA transferase <400> 2 Met Arg Lys Val Pro Ile Ile Thr Ala Asp Glu Ala Ala Lys Leu Ile 1 5 10 15 Lys Asp Gly Asp Thr Val Thr Thr Ser Gly Phe Val Gly Asn Ala Ile 20 25 30 Pro Glu Ala Leu Asp Arg Ala Val Glu Lys Arg Phe Leu Glu Thr Gly 35 40 45 Glu Pro Lys Asn Ile Thr Tyr Val Tyr Cys Gly Ser Gln Gly Asn Arg 50 55 60 Asp Gly Arg Gly Ala Glu His Phe Ala His Glu Gly Leu Leu Lys Arg 65 70 75 80 Tyr Ile Ala Gly His Trp Ala Thr Val Pro Ala Leu Gly Lys Met Ala 85 90 95 Met Glu Asn Lys Met Glu Ala Tyr Asn Val Ser Gln Gly Ala Leu Cys 100 105 110 His Leu Phe Arg Asp Ile Ala Ser His Lys Pro Gly Val Phe Thr Lys 115 120 125 Val Gly Ile Gly Thr Phe Ile Asp Pro Arg Asn Gly Gly Gly Lys Val 130 135 140 Asn Asp Ile Thr Lys Glu Asp Ile Val Glu Leu Val Glu Ile Lys Gly 145 150 155 160 Gln Glu Tyr Leu Phe Tyr Pro Ala Phe Pro Ile His Val Ala Leu Ile 165 170 175 Arg Gly Thr Tyr Ala Asp Glu Ser Gly Asn Ile Thr Phe Glu Lys Glu 180 185 190 Val Ala Pro Leu Glu Gly Thr Ser Val Cys Gln Ala Val Lys Asn Ser 195 200 205 Gly Gly Ile Val Val Val Gln Val Glu Arg Val Val Lys Ala Gly Thr 210 215 220 Leu Asp Pro Arg His Val Lys Val Pro Gly Ile Tyr Val Asp Tyr Val 225 230 235 240 Val Val Ala Asp Pro Glu Asp His Gln Gln Ser Leu Asp Cys Glu Tyr 245 250 255 Asp Pro Ala Leu Ser Gly Glu His Arg Arg Pro Glu Val Val Gly Glu 260 265 270 Pro Leu Pro Leu Ser Ala Lys Lys Val Ile Gly Arg Arg Gly Ala Ile 275 280 285 Glu Leu Glu Lys Asp Val Ala Val Asn Leu Gly Val Gly Ala Pro Glu 290 295 300 Tyr Val Ala Ser Val Ala Asp Glu Glu Gly Ile Val Asp Phe Met Thr 305 310 315 320 Leu Thr Ala Glu Ser Gly Ala Ile Gly Gly Val Pro Ala Gly Gly Val 325 330 335 Arg Phe Gly Ala Ser Tyr Asn Ala Asp Ala Leu Ile Asp Gln Gly Tyr 340 345 350 Gln Phe Asp Tyr Tyr Asp Gly Gly Gly Leu Asp Leu Cys Tyr Leu Gly 355 360 365 Leu Ala Glu Cys Asp Glu Lys Gly Asn Ile Asn Val Ser Arg Phe Gly 370 375 380 Pro Arg Ile Ala Gly Cys Gly Gly Phe Ile Asn Ile Thr Gln Asn Thr 385 390 395 400 Pro Lys Val Phe Phe Cys Gly Thr Phe Thr Ala Gly Gly Leu Lys Val 405 410 415 Lys Ile Glu Asp Gly Lys Val Ile Ile Val Gln Glu Gly Lys Gln Lys 420 425 430 Lys Phe Leu Lys Ala Val Glu Gln Ile Thr Phe Asn Gly Asp Val Ala 435 440 445 Leu Ala Asn Lys Gln Gln Val Thr Tyr Ile Thr Glu Arg Cys Val Phe 450 455 460 Leu Leu Lys Glu Asp Gly Leu His Leu Ser Glu Ile Ala Pro Gly Ile 465 470 475 480 Asp Leu Gln Thr Gln Ile Leu Asp Val Met Asp Phe Ala Pro Ile Ile 485 490 495 Asp Arg Asp Ala Asn Gly Gln Ile Lys Leu Met Asp Ala Ala Leu Phe 500 505 510 Ala Glu Gly Leu Met Gly Leu Lys Glu Met Lys Ser 515 520 <210> 3 <211> 1677 <212> DNA <213> Pseudomonas sp. 6-19 <220> <221> gene <222> (1)..(1677) <223> PHA synthase <400> 3 atgagtaaca agagtaacga tgagttgaag tatcaagcct ctgaaaacac cttggggctt 60 aatcctgtcg ttgggctgcg tggaaaggat ctactggctt ctgctcgaat ggtgcttagg 120 caggccatca agcaaccggt gcacagcgtc aaacatgtcg cgcactttgg tcttgaactc 180 aagaacgtac tgctgggtaa atccgggctg caaccgacca gcgatgaccg tcgcttcgcc 240 gatccggcct ggagccagaa cccgctctat aaacgttatt tgcaaaccta cctggcgtgg 300 cgcaaggaac tccacgactg gatcgatgaa agtaacctcg cccccaagga tgtggcgcgt 360 gggcacttcg tgatcaacct catgaccgaa gcgatggcgc cgaccaacac cgcggccaac 420 ccggcggcag tcaaacgctt ttttgaaacc ggtggcaaaa gcctgctcga cggcctctcg 480 cacctggcca aggatctggt acacaacggc ggcatgccga gccaggtcaa catgggtgca 540 ttcgaggtcg gcaagagcct gggcgtgacc gaaggcgcgg tggtgtttcg caacgatgtg 600 ctggaactga tccagtacaa gccgaccacc gagcaggtat acgaacgccc gctgctggtg 660 gtgccgccgc agatcaacaa gttctacgtt ttcgacctga gcccggacaa gagcctggcg 720 cggttctgcc tgcgcaacaa cgtgcaaacg ttcatcgtca gctggcgaaa tcccaccaag 780 gaacagcgag agtggggcct gtcgacctac atcgaagccc tcaaggaagc ggttgacgtc 840 gttaccgcga tcaccggcag caaagacgtg aacatgctcg gggcctgctc cggcggcatc 900 acttgcactg cgctgctggg ccattacgcg gcgattggcg aaaacaaggt caacgccctg 960 accttgctgg tgagcgtgct tgataccacc ctcgacagcg acgtcgccct gttcgtcaat 1020 gaacagaccc ttgaagccgc caagcgccac tcgtaccagg ccggcgtact ggaaggccgc 1080 gacatggcga aggtcttcgc ctggatgcgc cccaacgatc tgatctggaa ctactgggtc 1140 aacaattacc tgctaggcaa cgaaccgccg gtgttcgaca tcctgttctg gaacaacgac 1200 accacacggt tgcccgcggc gttccacggc gacctgatcg aactgttcaa aaataaccca 1260 ctgattcgcc cgaatgcact ggaagtgtgc ggcaccccca tcgacctcaa gcaggtgacg 1320 gccgacatct tttccctggc cggcaccaac gaccacatca ccccgtggaa gtcctgctac 1380 aagtcggcgc aactgtttgg cggcaacgtt gaattcgtgc tgtcgagcag cgggcatatc 1440 cagagcatcc tgaacccgcc gggcaatccg aaatcgcgct acatgaccag caccgaagtg 1500 gcggaaaatg ccgatgaatg gcaagcgaat gccaccaagc atacagattc ctggtggctg 1560 cactggcagg cctggcaggc ccaacgctcg ggcgagctga aaaagtcccc gacaaaactg 1620 ggcagcaagg cgtatccggc aggtgaagcg gcgccaggca cgtacgtgca cgaacgg 1677 <210> 4 <211> 559 <212> PRT <213> Pseudomonas sp. 6-19 <220> <221> PEPTIDE <222> (1)..(559) <223> PHA synthase <400> 4 Met Ser Asn Lys Ser Asn Asp Glu Leu Lys Tyr Gln Ala Ser Glu Asn 1 5 10 15 Thr Leu Gly Leu Asn Pro Val Val Gly Leu Arg Gly Lys Asp Leu Leu 20 25 30 Ala Ser Ala Arg Met Val Leu Arg Gln Ala Ile Lys Gln Pro Val His 35 40 45 Ser Val Lys His Val Ala His Phe Gly Leu Glu Leu Lys Asn Val Leu 50 55 60 Leu Gly Lys Ser Gly Leu Gln Pro Thr Ser Asp Asp Arg Arg Phe Ala 65 70 75 80 Asp Pro Ala Trp Ser Gln Asn Pro Leu Tyr Lys Arg Tyr Leu Gln Thr 85 90 95 Tyr Leu Ala Trp Arg Lys Glu Leu His Asp Trp Ile Asp Glu Ser Asn 100 105 110 Leu Ala Pro Lys Asp Val Ala Arg Gly His Phe Val Ile Asn Leu Met 115 120 125 Thr Glu Ala Met Ala Pro Thr Asn Thr Ala Ala Asn Pro Ala Ala Val 130 135 140 Lys Arg Phe Phe Glu Thr Gly Gly Lys Ser Leu Leu Asp Gly Leu Ser 145 150 155 160 His Leu Ala Lys Asp Leu Val His Asn Gly Gly Met Pro Ser Gln Val 165 170 175 Asn Met Gly Ala Phe Glu Val Gly Lys Ser Leu Gly Val Thr Glu Gly 180 185 190 Ala Val Val Phe Arg Asn Asp Val Leu Glu Leu Ile Gln Tyr Lys Pro 195 200 205 Thr Thr Glu Gln Val Tyr Glu Arg Pro Leu Leu Val Val Pro Pro Gln 210 215 220 Ile Asn Lys Phe Tyr Val Phe Asp Leu Ser Pro Asp Lys Ser Leu Ala 225 230 235 240 Arg Phe Cys Leu Arg Asn Asn Val Gln Thr Phe Ile Val Ser Trp Arg 245 250 255 Asn Pro Thr Lys Glu Gln Arg Glu Trp Gly Leu Ser Thr Tyr Ile Glu 260 265 270 Ala Leu Lys Glu Ala Val Asp Val Val Thr Ala Ile Thr Gly Ser Lys 275 280 285 Asp Val Asn Met Leu Gly Ala Cys Ser Gly Gly Ile Thr Cys Thr Ala 290 295 300 Leu Leu Gly His Tyr Ala Ala Ile Gly Glu Asn Lys Val Asn Ala Leu 305 310 315 320 Thr Leu Leu Val Ser Val Leu Asp Thr Thr Leu Asp Ser Asp Val Ala 325 330 335 Leu Phe Val Asn Glu Gln Thr Leu Glu Ala Ala Lys Arg His Ser Tyr 340 345 350 Gln Ala Gly Val Leu Glu Gly Arg Asp Met Ala Lys Val Phe Ala Trp 355 360 365 Met Arg Pro Asn Asp Leu Ile Trp Asn Tyr Trp Val Asn Asn Tyr Leu 370 375 380 Leu Gly Asn Glu Pro Pro Val Phe Asp Ile Leu Phe Trp Asn Asn Asp 385 390 395 400 Thr Thr Arg Leu Pro Ala Ala Phe His Gly Asp Leu Ile Glu Leu Phe 405 410 415 Lys Asn Asn Pro Leu Ile Arg Pro Asn Ala Leu Glu Val Cys Gly Thr 420 425 430 Pro Ile Asp Leu Lys Gln Val Thr Ala Asp Ile Phe Ser Leu Ala Gly 435 440 445 Thr Asn Asp His Ile Thr Pro Trp Lys Ser Cys Tyr Lys Ser Ala Gln 450 455 460 Leu Phe Gly Gly Asn Val Glu Phe Val Leu Ser Ser Ser Gly His Ile 465 470 475 480 Gln Ser Ile Leu Asn Pro Pro Gly Asn Pro Lys Ser Arg Tyr Met Thr 485 490 495 Ser Thr Glu Val Ala Glu Asn Ala Asp Glu Trp Gln Ala Asn Ala Thr 500 505 510 Lys His Thr Asp Ser Trp Trp Leu His Trp Gln Ala Trp Gln Ala Gln 515 520 525 Arg Ser Gly Glu Leu Lys Lys Ser Pro Thr Lys Leu Gly Ser Lys Ala 530 535 540 Tyr Pro Ala Gly Glu Ala Ala Pro Gly Thr Tyr Val His Glu Arg 545 550 555 <210> 5 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 5 gagagacaat caaatcatga gtaacaagag taacg 35 <210> 6 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 6 cactcatgca agcgtcaccg ttcgtgcacg tac 33 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 7 atgcccggag ccggttcgaa 20 <210> 8 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 8 cgttactctt gttactcatg atttgattgt ctctc 35 <210> 9 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 9 gagagacaat caaatcatga gtaacaagag taacg 35 <210> 10 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 10 cactcatgca agcgtcaccg ttcgtgcacg tac 33 <210> 11 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 11 gtacgtgcac gaacggtgac gcttgcatga gtg 33 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 12 aacgggaggg aacctgcagg 20 <210> 13 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 13 ctgaccttgc tggtgaccgt gcttgatacc acc 33 <210> 14 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 14 ggtggtatca agcacggtca ccagcaaggt cag 33 <210> 15 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 15 cgagcagcgg gcatatcatg agcatcctga acccgc 36 <210> 16 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 16 gcgggttcag gatgctcatg atatgcccgc tgctcg 36 <210> 17 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 17 atcaacctca tgaccgatgc gatggcgccg acc 33 <210> 18 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 18 ggtcggcgcc atcgcatcgg tcatgaggtt gat 33 <210> 19 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 19 ggaattcatg agaaaggttc ccattattac cgcagatga 39 <210> 20 <211> 46 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 20 gctctagatt aggacttcat ttccttcaga cccattaagc cttctg 46 <210> 21 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 21 aggcctgcag gcggataaca atttcacaca gg 32 <210> 22 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 22 gcccatatgt ctagattagg acttcatttc c 31 <210> 23 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 23 cgccggcagg cctgcagg 18 <210> 24 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 24 ggcaggtcag cccatatgtc 20 <210> 25 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 25 gaattcgtgc tgtcgagccg cgggcatatc 30 <210> 26 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 26 gatatgcccg cggctcgaca gcacgaattc 30 <210> 27 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 27 gggcatatca agagcatcct gaacccgc 28 <210> 28 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 28 gcgggttcag gatgctcttg atatgccc 28 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 29 atgcccggag ccggttcgaa 20 <210> 30 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 30 gaaattgtta tccgcctgca gg 22 <210> 31 <211> 72 <212> DNA <213> Artificial Sequence <220> <223> oligomer <400> 31 atcagcgtac ccgtgatgct aacttctctc tggaaggtct gaccggcttt aattaaccct 60 cactaaaggg cg 72 <210> 32 <211> 72 <212> DNA <213> Artificial Sequence <220> <223> oligomer <400> 32 atcagcgtac ccgtgatgct aacttctctc tggaaggtct gaccggcttt aattaaccct 60 cactaaaggg cg 72 <110> LG CHEM, LTD. Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same <130> DPP20147706KR <160> 32 <170> Kopatentin 1.71 <210> 1 <211> 1575 <212> DNA <213> Clostridium propionicum <220> <221> gene ≪ 222 > (1) .. (1575) <223> popionyl-CoA transferase <400> 1 atgagaaagg ttcccattat taccgcagat gaggctgcaa agcttattaa agacggtgat 60 acagttacaa caagtggttt cgttggaaat gcaatccctg aggctcttga tagagctgta 120 gaaaaaagat tcttagaaac aggcgaaccc aaaaacatta cctatgttta ttgtggttct 180 caaggtaaca gagacggaag aggtgctgag cactttgctc atgaaggcct tttaaaacgt 240 tacatcgctg gtcactgggc tacagttcct gctttgggta aaatggctat ggaaaataaa 300 atggaagcat ataatgtatc tcagggtgca ttgtgtcatt tgttccgtga tatagcttct 360 cataagccag gcgtatttac aaaggtaggt atcggtactt tcattgaccc cagaaatggc 420 ggcggtaaag taaatgatat taccaaagaa gatattgttg aattggtaga gattaagggt 480 caggaatatt tattctaccc tgcttttcct attcatgtag ctcttattcg tggtacttac 540 gctgatgaaa gcggaaatat cacatttgag aaagaagttg ctcctctgga aggaacttca 600 gtatgccagg ctgttaaaaa cagtggcggt atcgttgtag ttcaggttga aagagtagta 660 aaagctggta ctcttgaccc tcgtcatgta aaagttccag gaatttatgt tgactatgtt 720 gttgttgctg acccagaaga tcatcagcaa tctttagatt gtgaatatga tcctgcatta 780 tcaggcgagc atagaagacc tgaagttgtt ggagaaccac ttcctttgag tgcaaagaaa 840 gttattggtc gtcgtggtgc cattgaatta gaaaaagatg ttgctgtaaa tttaggtgtt 900 ggtgcgcctg aatatgtagc aagtgttgct gatgaagaag gtatcgttga ttttatgact 960 ttaactgctg aaagtggtgc tattggtggt gttcctgctg gtggcgttcg ctttggtgct 1020 tcttataatg cggatgcatt gatcgatcaa ggttatcaat tcgattacta tgatggcggc 1080 ggcttagacc tttgctattt aggcttagct gaatgcgatg aaaaaggcaa tatcaacgtt 1140 tcaagatttg gccctcgtat cgctggttgt ggtggtttca tcaacattac acagaataca 1200 cctaaggtat tcttctgtgg tactttcaca gcaggtggct taaaggttaa aattgaagat 1260 ggcaaggtta ttattgttca agaaggcaag cagaaaaaaat tcttgaaagc tgttgagcag 1320 attacattca atggtgacgt tgcacttgct aataagcaac aagtaactta tattacagaa 1380 agatgcgtat tccttttgaa ggaagatggt ttgcacttat ctgaaattgc acctggtatt 1440 gatttgcaga cacagattct tgacgttatg gattttgcac ctattattga cagagatgca 1500 aacggccaaa tcaaattgat ggacgctgct ttgtttgcag aaggcttaat gggtctgaag 1560 gaaatgaagt cctaa 1575 <210> 2 <211> 524 <212> PRT <213> Clostridium propionicum <220> <221> PEPTIDE ≪ 222 > (1) .. (524) <223> propionyl-CoA transferase <400> 2 Met Arg Lys Val Pro Ile Ile Thr Ala Asp Glu Ala Ala Lys Leu Ile 1 5 10 15 Lys Asp Gly Asp Thr Val Thr Thr Ser Gly Phe Val Gly Asn Ala Ile 20 25 30 Pro Glu Ala Leu Asp Arg Ala Val Glu Lys Arg Phe Leu Glu Thr Gly 35 40 45 Glu Pro Lys Asn Ile Thr Tyr Val Tyr Cys Gly Ser Gln Gly Asn Arg 50 55 60 Asp Gly Arg Gly Ala Glu His Phe Ala His Glu Gly Leu Leu Lys Arg 65 70 75 80 Tyr Ile Ala Gly His Trp Ala Thr Val Ala Leu Gly Lys Met Ala 85 90 95 Met Glu Asn Lys Met Glu Ala Tyr Asn Val Ser Gln Gly Ala Leu Cys 100 105 110 His Leu Phe Arg Asp Ile Ala Ser His Lys Pro Gly Val Phe Thr Lys 115 120 125 Val Gly Ile Gly Thr Phe Ile Asp Pro Arg Asn Gly Gly Gly Lys Val 130 135 140 Asn Asp Ile Thr Lys Glu Asp Ile Val Glu Leu Val Glu Ile Lys Gly 145 150 155 160 Gln Glu Tyr Leu Phe Tyr Pro Ala Phe Pro Ile His Val Ala Leu Ile 165 170 175 Arg Gly Thr Tyr Ala Asp Glu Ser Gly Asn Ile Thr Phe Glu Lys Glu 180 185 190 Val Ala Pro Leu Glu Gly Thr Ser Val Cys Gln Ala Val Lys Asn Ser 195 200 205 Gly Gly Ile Val Val Gly Val Glu Arg Val Val Lys Ala Gly Thr 210 215 220 Leu Asp Pro Arg His Val Lys Val Pro Gly Ile Tyr Val Asp Tyr Val 225 230 235 240 Val Val Ala Asp Pro Glu Asp His Gln Gln Ser Leu Asp Cys Glu Tyr 245 250 255 Asp Pro Ala Leu Ser Gly Glu His Arg Arg Pro Glu Val Val Gly Glu 260 265 270 Pro Leu Pro Leu Ser Ala Lys Lys Val Ile Gly Arg Arg Gly Ala Ile 275 280 285 Glu Leu Glu Lys Asp Val Ala Val Asn Leu Gly Val Gly Ala Pro Glu 290 295 300 Tyr Val Ala Ser Val Ala Asp Glu Glu Gly Ile Val Asp Phe Met Thr 305 310 315 320 Leu Thr Ala Glu Aly Gly Aly Gly Aly Gly Gly Val Ala Gly Gly Val 325 330 335 Arg Phe Gly Ala Ser Tyr Asn Ala Asp Ala Leu Ile Asp Gln Gly Tyr 340 345 350 Gln Phe Asp Tyr Tyr Asp Gly Gly Gly Leu Asp Leu Cys Tyr Leu Gly 355 360 365 Leu Ala Glu Cys Asp Glu Lys Gly Asn Ile Asn Val Ser Arg Phe Gly 370 375 380 Pro Arg Ile Ala Gly Cys Gly Gly Phe Ile Asn Ile Thr Gln Asn Thr 385 390 395 400 Pro Lys Val Phe Phe Cys Gly Thr Phe Thr Ala Gly Gly Leu Lys Val 405 410 415 Lys Ile Glu Asp Gly Lys Val Ile Ile Val Gln Glu Gly Lys Gln Lys 420 425 430 Lys Phe Leu Lys Ala Val Glu Gln Ile Thr Phe Asn Gly Asp Val Ala 435 440 445 Leu Ala Asn Lys Gln Gln Val Thr Tyr Ile Thr Glu Arg Cys Val Phe 450 455 460 Leu Leu Lys Glu Asp Gly Leu His Leu Ser Glu Ile Ala Pro Gly Ile 465 470 475 480 Asp Leu Gln Thr Gln Ile Leu Asp Val Met Asp Phe Ala Pro Ile Ile 485 490 495 Asp Arg Asp Ala Asn Gly Gln Ile Lys Leu Met Asp Ala Ala Leu Phe 500 505 510 Ala Glu Gly Leu Met Gly Leu Lys Glu Met Lys Ser 515 520 <210> 3 <211> 1677 <212> DNA <213> Pseudomonas sp. 6-19 <220> <221> gene <222> (1) .. (1677) <223> PHA synthase <400> 3 atgagtaaca agagtaacga tgagttgaag tatcaagcct ctgaaaacac cttggggctt 60 aatcctgtcg ttgggctgcg tggaaaggat ctactggctt ctgctcgaat ggtgcttagg 120 caggccatca agcaaccggt gcacagcgtc aaacatgtcg cgcactttgg tcttgaactc 180 aagaacgtac tgctgggtaa atccgggctg caaccgacca gcgatgaccg tcgcttcgcc 240 gatccggcct ggagccagaa cccgctctat aaacgttatt tgcaaaccta cctggcgtgg 300 cgcaaggaac tccacgactg gatcgatgaa agtaacctcg cccccaagga tgtggcgcgt 360 gggcacttcg tgatcaacct catgaccgaa gcgatggcgc cgaccaacac cgcggccaac 420 ccggcggcag tcaaacgctt ttttgaaacc ggtggcaaaa gcctgctcga cggcctctcg 480 cacctggcca aggatctggt acacaacggc ggcatgccga gccaggtcaa catgggtgca 540 ttcgaggtcg gcaagagcct gggcgtgacc gaaggcgcgg tggtgtttcg caacgatgtg 600 ctggaactga tccagtacaa gccgaccacc gagcaggtat acgaacgccc gctgctggtg 660 gtgccgccgc agatcaacaa gttctacgtt ttcgacctga gcccggacaa gagcctggcg 720 cggttctgcc tgcgcaacaa cgtgcaaacg ttcatcgtca gctggcgaaa tcccaccaag 780 gaacagcgag agtggggcct gtcgacctac atcgaagccc tcaaggaagc ggttgacgtc 840 gttaccgcga tcaccggcag caaagacgtg aacatgctcg gggcctgctc cggcggcatc 900 acttgcactg cgctgctggg ccattacgcg gcgattggcg aaaacaaggt caacgccctg 960 accttgctgg tgagcgtgct tgataccacc ctcgacagcg acgtcgccct gttcgtcaat 1020 gaacagaccc ttgaagccgc caagcgccac tcgtaccagg ccggcgtact ggaaggccgc 1080 gacatggcga aggtcttcgc ctggatgcgc cccaacgatc tgatctggaa ctactgggtc 1140 aacaattacc tgctaggcaa cgaaccgccg gtgttcgaca tcctgttctg gaacaacgac 1200 accacacggt tgcccgcggc gttccacggc gacctgatcg aactgttcaa aaataaccca 1260 ctgattcgcc cgaatgcact ggaagtgtgc ggcaccccca tcgacctcaa gcaggtgacg 1320 gccgacatct tttccctggc cggcaccaac gaccacatca ccccgtggaa gtcctgctac 1380 aagtcggcgc aactgtttgg cggcaacgtt gaattcgtgc tgtcgagcag cgggcatatc 1440 cagagcatcc tgaacccgcc gggcaatccg aaatcgcgct acatgaccag caccgaagtg 1500 gcggaaaatg ccgatgaatg gcaagcgaat gccaccaagc atacagattc ctggtggctg 1560 cactggcagg cctggcaggc ccaacgctcg ggcgagctga aaaagtcccc gacaaaactg 1620 ggcagcaagg cgtatccggc aggtgaagcg gcgccaggca cgtacgtgca cgaacgg 1677 <210> 4 <211> 559 <212> PRT <213> Pseudomonas sp. 6-19 <220> <221> PEPTIDE ≪ 222 > (1) .. (559) <223> PHA synthase <400> 4 Met Ser Asn Lys Ser Asn Asp Glu Leu Lys Tyr Gln Ala Ser Glu Asn 1 5 10 15 Thr Leu Gly Leu Asn Pro Val Val Gly Leu Arg Gly Lys Asp Leu Leu 20 25 30 Ala Ser Ala Arg Met Val Leu Arg Gln Ala Ile Lys Gln Pro Val His 35 40 45 Ser Val Lys His Val Ala His Phe Gly Leu Glu Leu Lys Asn Val Leu 50 55 60 Leu Gly Lys Ser Gly Leu Gln Pro Thr Ser Asp Arg Arg Phe Ala 65 70 75 80 Asp Pro Ala Trp Ser Gln Asn Pro Leu Tyr Lys Arg Tyr Leu Gln Thr 85 90 95 Tyr Leu Ala Trp Arg Lys Glu Leu His Asp Trp Ile Asp Glu Ser Asn 100 105 110 Leu Ala Pro Lys Asp Val Ala Arg Gly His Phe Val Ile Asn Leu Met 115 120 125 Thr Glu Ala Met Ala Pro Thr Asn Thr Ala Ala Asn Pro Ala Ala Val 130 135 140 Lys Arg Phe Phe Glu Thr Gly Gly Lys Ser Leu Leu Asp Gly Leu Ser 145 150 155 160 His Leu Ala Lys Asp Leu Val His Asn Gly Gly Met Pro Ser Gln Val 165 170 175 Asn Met Gly Ala Phe Glu Val Gly Lys Ser Leu Gly Val Thr Glu Gly 180 185 190 Ala Val Val Phe Arg Asn Asp Val Leu Glu Leu Ile Gln Tyr Lys Pro 195 200 205 Thr Thr Glu Gln Val Tyr Glu Arg Pro Leu Leu Val Val Pro Pro Gln 210 215 220 Ile Asn Lys Phe Tyr Val Phe Asp Leu Ser Pro Asp Lys Ser Leu Ala 225 230 235 240 Arg Phe Cys Leu Arg Asn Asn Val Gln Thr Phe Ile Val Ser Trp Arg 245 250 255 Asn Pro Thr Lys Glu Gln Arg Glu Trp Gly Leu Ser Thr Tyr Ile Glu 260 265 270 Ala Leu Lys Glu Ala Val Asp Val Val Thr Ala Ile Thr Gly Ser Lys 275 280 285 Asp Val Asn Met Leu Gly Ala Cys Ser Gly Gly Ile Thr Cys Thr Ala 290 295 300 Leu Leu Gly His Tyr Ala Ile Gly Glu Asn Lys Val Asn Ala Leu 305 310 315 320 Thr Leu Leu Val Ser Val Leu Asp Thr Thr Leu Asp Ser Asp Val Ala 325 330 335 Leu Phe Val Asn Glu Gln Thr Leu Glu Ala Ala Lys Arg His Ser Tyr 340 345 350 Gln Ala Gly Val Leu Glu Gly Arg Asp Met Ala Lys Val Phe Ala Trp 355 360 365 Met Arg Pro Asn Asp Leu Ile Trp Asn Tyr Trp Val Asn Asn Tyr Leu 370 375 380 Leu Gly Asn Glu Pro Pro Val Phe Asp Ile Leu Phe Trp Asn Asn Asp 385 390 395 400 Thr Thr Arg Leu Pro Ala Ala Phe His Gly Asp Leu Ile Glu Leu Phe 405 410 415 Lys Asn Asn Pro Leu Ile Arg Pro Asn Ala Leu Glu Val Cys Gly Thr 420 425 430 Pro Ile Asp Leu Lys Gln Val Thr Ala Asp Ile Phe Ser Leu Ala Gly 435 440 445 Thr Asn Asp His Ile Thr Pro Trp Lys Ser Cys Tyr Lys Ser Ala Gln 450 455 460 Leu Phe Gly Gly Asn Val Glu Phe Val Leu Ser Ser Ser Gly His Ile 465 470 475 480 Gln Ser Ile Leu Asn Pro Pro Gly Asn Pro Lys Ser Arg Tyr Met Thr 485 490 495 Ser Thr Glu Val Ala Glu Asn Ala Asp Glu Trp Gln Ala Asn Ala Thr 500 505 510 Lys His Thr Asp Ser Trp Trp Leu His Trp Gln Ala Trp Gln Ala Gln 515 520 525 Arg Ser Gly Glu Leu Lys Lys Ser Pro Thr Lys Leu Gly Ser Lys Ala 530 535 540 Tyr Pro Ala Gly Glu Ala Ala Pro Gly Thr Tyr Val His Glu Arg 545 550 555 <210> 5 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 5 gagagacaat caaatcatga gtaacaagag taacg 35 <210> 6 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 6 cactcatgca agcgtcaccg ttcgtgcacg tac 33 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 7 atgcccggag ccggttcgaa 20 <210> 8 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 8 cgttactctt gttactcatg atttgattgt ctctc 35 <210> 9 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 9 gagagacaat caaatcatga gtaacaagag taacg 35 <210> 10 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 10 cactcatgca agcgtcaccg ttcgtgcacg tac 33 <210> 11 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 11 gtacgtgcac gaacggtgac gcttgcatga gtg 33 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 12 aacgggaggg aacctgcagg 20 <210> 13 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 13 ctgaccttgc tggtgaccgt gcttgatacc acc 33 <210> 14 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 14 ggtggtatca agcacggtca ccagcaaggt cag 33 <210> 15 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 15 cgagcagcgg gcatatcatg agcatcctga acccgc 36 <210> 16 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 16 gcgggttcag gatgctcatg atatgcccgc tgctcg 36 <210> 17 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 17 atcaacctca tgaccgatgc gatggcgccg acc 33 <210> 18 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 18 ggtcggcgcc atcgcatcgg tcatgaggtt gat 33 <210> 19 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 19 ggaattcatg agaaaggttc ccattattac cgcagatga 39 <210> 20 <211> 46 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 20 gctctagatt aggacttcat ttccttcaga cccattaagc cttctg 46 <210> 21 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 21 aggcctgcag gcggataaca atttcacaca gg 32 <210> 22 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 22 gcccatatgt ctagattagg acttcatttc c 31 <210> 23 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 23 cgccggcagg cctgcagg 18 <210> 24 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 24 ggcaggtcag cccatatgtc 20 <210> 25 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 25 gaattcgtgc tgtcgagccg cgggcatatc 30 <210> 26 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 26 gatatgcccg cggctcgaca gcacgaattc 30 <210> 27 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 27 gggcatatca agagcatcct gaacccgc 28 <210> 28 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 28 gcgggttcag gatgctcttg atatgccc 28 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 29 atgcccggag ccggttcgaa 20 <210> 30 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 30 gaaattgtta tccgcctgca gg 22 <210> 31 <211> 72 <212> DNA <213> Artificial Sequence <220> <223> oligomer <400> 31 atcagcgtac ccgtgatgct aacttctctc tggaaggtct gaccggcttt aattaaccct 60 cactaaaggg cg 72 <210> 32 <211> 72 <212> DNA <213> Artificial Sequence <220> <223> oligomer <400> 32 atcagcgtac ccgtgatgct aacttctctc tggaaggtct gaccggcttt aattaaccct 60 cactaaaggg cg 72
Claims (15)
4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units.
4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체의 제조방법.
The activity of lactate dehydrogenase is weakened or deficient, the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, and the 2-hydroxyalkanoyl- 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoate is converted into 4-hydroxyalkanoate. A gene encoding an enzyme that converts to 4-hydroxyalkanoyl-CoA, and 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl-CoA as substrates Comprising the step of culturing a microorganism comprising a gene encoding a polyhydroxyalkanoate (PHA) synthase,
4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units.
The microorganism according to claim 2, wherein the microorganism converts 2-hydroxyalkanoate into 2-hydroxyalkanoyl-CoA, converts 3-hydroxyalkanoate into 3-hydroxyalkanoyl-CoA, A gene encoding an enzyme that converts 4-hydroxyalkanoate to 4-hydroxyalkanoyl-CoA, and a gene encoding 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA, and 4-hydroxyalkanoyl Which is obtained by transforming a gene encoding PHA synthetase using -CoA as a substrate.
The method of claim 2, wherein the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, Wherein the enzyme converting the Roxy alkanoate to 4-hydroxyalkanoyl-CoA is propionyl-CoA transferase.
(a) 서열번호 1의 염기서열;
(b) 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(c) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이된 염기서열;
(d) 서열번호 1과 대응하는 아미노산 서열에서 Gly335Asp이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(e) 서열번호 1과 대응하는 아미노산 서열에서 Ala243Thr이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(f) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Gly이 변이되고, 서열번호 1 의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;
(g) 서열번호 1과 대응하는 아미노산 서열에서 Asp257Asn이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(h) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Asn이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;
(i) 서열번호 1과 대응하는 아미노산 서열에서 Thr199Ile이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열; 및
(j) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이되고, 서열번호 1과 대응하는 아미노산 서열에서 Val193Ala이 변이된 염기서열
로 이루어진 군으로부터 선택된 염기서열로 이루어진 것인 제조방법.
The method of claim 2, wherein the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, The gene encoding the enzyme that converts the Roxy alkanoate to 4-hydroxyalkanoyl-
(a) a nucleotide sequence of SEQ ID NO: 1;
(b) a base sequence in which A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(c) a base sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(d) a base sequence in which Gly335Asp is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(e) a base sequence in which Ala243Thr is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(f) a base sequence in which Asp65Gly is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(g) a nucleotide sequence in which Asp257Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(h) a nucleotide sequence in which Asp65Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(i) a base sequence in which Thr199Ile is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1; And
(j) a nucleotide sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1 and Val193Ala is mutated in the amino acid sequence corresponding to SEQ ID NO: 1
≪ / RTI >
The production method according to claim 2, wherein the polyhydroxyalkanoate synthase is a polyhydroxyalkanoate synthase derived from Pseudomonas sp. 6-19.
서열번호 4의 아미노산 서열; 또는
서열번호 4의 아미노산 서열에서 L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R 및 A527S로 구성되는 군으로부터 선택되는 하나 이상의 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것인 제조방법.
3. The polyhydroxyalkanoate synthase according to claim 2, wherein the gene encoding the polyhydroxyalkanoate-
The amino acid sequence of SEQ ID NO: 4; or
At least one mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R and A527S in the amino acid sequence of SEQ ID NO: ≪ / RTI > wherein the nucleotide sequence is a nucleotide sequence corresponding to the amino acid sequence.
서열번호 4의 아미노산 서열에서,
(i) S325T 및 Q481M;
(ii) E130D, S325T 및 Q481M;
(iii) E130D, S325T, S477R 및 Q481M;
(iv) E130D, S477F 및 Q481K; 및
(v) L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K 및 A527S로 이루어진 군으로부터 선택되는 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것인 제조방법.
3. The polyhydroxyalkanoate synthase according to claim 2, wherein the gene encoding the polyhydroxyalkanoate-
In the amino acid sequence of SEQ ID NO: 4,
(i) S325T and Q481M;
(ii) E130D, S325T and Q481M;
(iii) E130D, S325T, S477R and Q481M;
(iv) E130D, S477F and Q481K; And
(v) a nucleotide sequence corresponding to an amino acid sequence comprising a mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K and A527S.
3. The process according to claim 2, wherein the culture is carried out in a medium comprising 2-hydroxybutyrate, 3-hydroxybutyrate and 4-hydroxybutyrate.
2-하이드록시알카노에트를 2-하이드록시알카노일-CoA로 전환하고, 3-하이드록시알카노에트를 3-하이드록시알카노일-CoA로 전환하고, 4-하이드록시알카노에트를 4-하이드록시알카노일-CoA로 전환하는 효소를 코딩하는 유전자, 및 2-하이드록시알카노일-CoA, 3-하이드록시알카노일-CoA 및 4-하이드록시알카노일-CoA 를 기질로 사용하는 PHA 합성효소를 코딩하는 유전자가 도입된,
4-하이드록시부티레이트, 3-하이드록시부티레이트 및 2-하이드록시부티레이트를 반복단위로 포함하는 삼중합체를 생산하는 미생물.
The activity of lactate dehydrogenase is weakened or deficient,
Hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, 4-hydroxyalkanoate is converted to 4- A gene encoding an enzyme that converts to hydroxyalkanoyl-CoA, and a PHA synthetase using 2-hydroxyalkanoyl-CoA, 3-hydroxyalkanoyl-CoA and 4-hydroxyalkanoyl- Lt; RTI ID = 0.0 >
A microorganism producing a terpolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating units.
11. The method of claim 10, wherein the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, The enzyme that converts Roxy alkanoate to 4-hydroxyalkanoyl-CoA is a propionyl-CoA transferase, a microorganism.
(a) 서열번호 1의 염기서열;
(b) 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(c) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이된 염기서열;
(d) 서열번호 1과 대응하는 아미노산 서열에서 Gly335Asp이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(e) 서열번호 1과 대응하는 아미노산 서열에서 Ala243Thr이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(f) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Gly이 변이되고, 서열번호 1 의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;
(g) 서열번호 1과 대응하는 아미노산 서열에서 Asp257Asn이 변이되고, 서열번호 1의 염기서열에서 A1200G가 변이된 염기서열;
(h) 서열번호 1과 대응하는 아미노산 서열에서 Asp65Asn이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열;
(i) 서열번호 1과 대응하는 아미노산 서열에서 Thr199Ile이 변이되고, 서열번호 1의 염기서열에서 T669C, A1125G 및 T1158C가 변이된 염기서열; 및
(j) 서열번호 1의 염기서열에서 T78C, T669C, A1125G 및 T1158C가 변이되고, 서열번호 1과 대응하는 아미노산 서열에서 Val193Ala이 변이된 염기서열
로 이루어진 군으로부터 선택된 염기서열로 이루어진 것인, 미생물.
11. The method of claim 10, wherein the 2-hydroxyalkanoate is converted to 2-hydroxyalkanoyl-CoA, the 3-hydroxyalkanoate is converted to 3-hydroxyalkanoyl-CoA, The gene encoding the enzyme that converts the Roxy alkanoate to 4-hydroxyalkanoyl-
(a) a nucleotide sequence of SEQ ID NO: 1;
(b) a base sequence in which A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(c) a base sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(d) a base sequence in which Gly335Asp is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(e) a base sequence in which Ala243Thr is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(f) a base sequence in which Asp65Gly is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(g) a nucleotide sequence in which Asp257Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1 and A1200G is mutated in the nucleotide sequence of SEQ ID NO: 1;
(h) a nucleotide sequence in which Asp65Asn is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1;
(i) a base sequence in which Thr199Ile is mutated in the amino acid sequence corresponding to SEQ ID NO: 1, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1; And
(j) a nucleotide sequence in which T78C, T669C, A1125G and T1158C are mutated in the nucleotide sequence of SEQ ID NO: 1 and Val193Ala is mutated in the amino acid sequence corresponding to SEQ ID NO: 1
≪ / RTI > wherein the nucleotide sequence is selected from the group consisting of: < RTI ID = 0.0 >
11. The microorganism according to claim 10, wherein the polyhydroxyalkanoate synthase is a polyhydroxyalkanoate synthase derived from Pseudomonas sp. 6-19.
서열번호 4의 아미노산 서열; 또는
서열번호 4의 아미노산 서열에서 L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R 및 A527S로 구성되는 군으로부터 선택되는 하나 이상의 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것인, 미생물.
11. The method according to claim 10, wherein the gene encoding the polyhydroxyalkanoate synthase is selected from the group consisting of:
The amino acid sequence of SEQ ID NO: 4; or
At least one mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477R, S477H, S477F, S477Y, S477G, Q481M, Q481K, Q481R and A527S in the amino acid sequence of SEQ ID NO: Wherein the nucleotide sequence is a nucleotide sequence corresponding to the amino acid sequence of SEQ ID NO:
서열번호 4의 아미노산 서열에서,
(i) S325T 및 Q481M;
(ii) E130D, S325T 및 Q481M;
(iii) E130D, S325T, S477R 및 Q481M;
(iv) E130D, S477F 및 Q481K; 및
(v) L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K 및 A527S로 이루어진 군으로부터 선택되는 변이를 포함하는 아미노산 서열에 대응하는 염기 서열로 이루어진 것인, 미생물.11. The method according to claim 10, wherein the gene encoding the polyhydroxyalkanoate synthase is selected from the group consisting of:
In the amino acid sequence of SEQ ID NO: 4,
(i) S325T and Q481M;
(ii) E130D, S325T and Q481M;
(iii) E130D, S325T, S477R and Q481M;
(iv) E130D, S477F and Q481K; And
(v) a nucleotide sequence corresponding to an amino acid sequence comprising a mutation selected from the group consisting of L18H, V24A, K91R, M128V, E130D, N246S, S325T, S477G, Q481K and A527S.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150125106A KR102088503B1 (en) | 2015-09-03 | 2015-09-03 | Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150125106A KR102088503B1 (en) | 2015-09-03 | 2015-09-03 | Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170028186A true KR20170028186A (en) | 2017-03-13 |
| KR102088503B1 KR102088503B1 (en) | 2020-03-12 |
Family
ID=58412133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150125106A Active KR102088503B1 (en) | 2015-09-03 | 2015-09-03 | Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102088503B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021049910A1 (en) | 2019-09-11 | 2021-03-18 | 주식회사 엘지화학 | Method for preparation of block copolymer |
| US11840604B2 (en) | 2019-03-26 | 2023-12-12 | Lg Chem, Ltd. | Process for preparation of block copolymer |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080045906A (en) * | 2006-11-21 | 2008-05-26 | 주식회사 엘지화학 | Novel hydroxybutyrate hydroxybutyrate lactate terpolymer and preparation method thereof |
| WO2008062999A1 (en) * | 2006-11-23 | 2008-05-29 | Lg Chem, Ltd. | Mutants of pha synthase from pseudomonas sp.6-19 and method for preparing lactate homopolymer or copolymer using the same |
| WO2008062995A1 (en) * | 2006-11-21 | 2008-05-29 | Lg Chem, Ltd. | Copolymer comprising 4-hydroxybutyrate unit and lactate unit and its manufacturing method |
| KR100957773B1 (en) * | 2006-11-23 | 2010-05-12 | 주식회사 엘지화학 | New 3-hydroxypropionate lactate copolymer and preparation method thereof |
| KR20120103997A (en) * | 2011-03-11 | 2012-09-20 | 한국과학기술원 | Recombinant microorganism producing polyhydroxyalkanoate (pha) containing 2-hydroxybutyrate (2hb) monomer and preparing method of pha containing 2hb using thereof |
| KR20130059308A (en) * | 2011-11-28 | 2013-06-05 | 주식회사 엘지화학 | Method of preparing for 2-hydroxyalkanoate polymer |
-
2015
- 2015-09-03 KR KR1020150125106A patent/KR102088503B1/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080045906A (en) * | 2006-11-21 | 2008-05-26 | 주식회사 엘지화학 | Novel hydroxybutyrate hydroxybutyrate lactate terpolymer and preparation method thereof |
| WO2008062995A1 (en) * | 2006-11-21 | 2008-05-29 | Lg Chem, Ltd. | Copolymer comprising 4-hydroxybutyrate unit and lactate unit and its manufacturing method |
| WO2008062999A1 (en) * | 2006-11-23 | 2008-05-29 | Lg Chem, Ltd. | Mutants of pha synthase from pseudomonas sp.6-19 and method for preparing lactate homopolymer or copolymer using the same |
| KR100957777B1 (en) | 2006-11-23 | 2010-05-12 | 주식회사 엘지화학 | PHA synthase variants derived from Pseudomonas genus 6-19 and methods for preparing lactate polymers or copolymers using the same |
| KR100957773B1 (en) * | 2006-11-23 | 2010-05-12 | 주식회사 엘지화학 | New 3-hydroxypropionate lactate copolymer and preparation method thereof |
| EP2089522B1 (en) * | 2006-11-23 | 2017-11-01 | LG Chem, Ltd. | Mutants of pha synthase from pseudomonas sp.6-19 and method for preparing lactate homopolymer or copolymer using the same |
| KR20120103997A (en) * | 2011-03-11 | 2012-09-20 | 한국과학기술원 | Recombinant microorganism producing polyhydroxyalkanoate (pha) containing 2-hydroxybutyrate (2hb) monomer and preparing method of pha containing 2hb using thereof |
| KR20130059308A (en) * | 2011-11-28 | 2013-06-05 | 주식회사 엘지화학 | Method of preparing for 2-hydroxyalkanoate polymer |
Non-Patent Citations (7)
| Title |
|---|
| Applied and Environmental Microbiology (2010) 76(15):4919-4925 * |
| Applied Microbiology and Biotechnology (2012) 93:273-283 * |
| Biotechnology Journal (2012) 7:199-212 * |
| Journal of Biotechnology (2013) 165:93-98 * |
| Journal of the Korean Industiral and Engineering Chemistry (2014) 25(2):134-141 * |
| Metabolic Engineering (2013) 20:20-28 * |
| Microbial Biotechnology (2013) 6(6):621-636 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840604B2 (en) | 2019-03-26 | 2023-12-12 | Lg Chem, Ltd. | Process for preparation of block copolymer |
| WO2021049910A1 (en) | 2019-09-11 | 2021-03-18 | 주식회사 엘지화학 | Method for preparation of block copolymer |
| CN114206977A (en) * | 2019-09-11 | 2022-03-18 | 株式会社Lg化学 | Method for preparing block copolymers |
| CN114206977B (en) * | 2019-09-11 | 2024-04-05 | 株式会社Lg化学 | Method for preparing block copolymers |
| US12371720B2 (en) | 2019-09-11 | 2025-07-29 | Lg Chem, Ltd. | Method for preparing block copolymer |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102088503B1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100957777B1 (en) | PHA synthase variants derived from Pseudomonas genus 6-19 and methods for preparing lactate polymers or copolymers using the same | |
| KR102088504B1 (en) | Copolymer comprising 3-hydroxypropionate, 2-hydroxybutyrate and lactate as repeating unit and method for preparing the same | |
| KR102519456B1 (en) | Method for preparing poly(3-hydroxypropionate-b-lactate) block copolymer by using microorganisms | |
| KR101045572B1 (en) | Propionyl-CoA Transferase Variants Derived from Cructostilridium Substances and Processes for Producing Lactate Polymers or Lactate Copolymers Using the Variants | |
| KR101037354B1 (en) | Recombinant microorganisms capable of producing polylactic acid or polylactic acid copolymers from sucrose and methods of preparing polylactic acid or lactic acid copolymers from sucrose using such microorganisms | |
| JP5626735B2 (en) | Recombinant Ralstonia eutropha having ability to produce polylactic acid or polylactic acid copolymer and method for producing polylactic acid or polylactic acid copolymer using the same | |
| KR101273599B1 (en) | Method for Preparing Polyhydroxyalkanoate Containing 2-Hydroxybutyrate | |
| KR20130059308A (en) | Method of preparing for 2-hydroxyalkanoate polymer | |
| KR102623585B1 (en) | Recombinant microorganism and method for preparing terpolymer comprising 2-hydroxybutyrate, 2-hydroxyisovalerate and lactate | |
| CN110382699B (en) | Methods of producing polyhydroxyalkanoates using 2-hydroxyisocaproate-CoA transferase | |
| KR102088503B1 (en) | Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate and 2-hydroxybutyrate as repeating unit and method for preparing the same | |
| KR102002096B1 (en) | Copolymer comprising 4-hydroxybutyrate, 2-hydroxybutyrate and lactate as repeating unit and method for preparing the same | |
| KR102538109B1 (en) | Method of Preparing PLA Homopolymer Using Recombinant Microorganism Comprising ldhD Gene | |
| JP6853787B2 (en) | A PHA-producing microorganism having sucrose assimilation property, and a method for producing PHA using the microorganism. | |
| KR102361618B1 (en) | Copolymer comprising 2-hydroxybutyrate and 3-hydroxybutyrate and method of preparing the same | |
| KR20200145119A (en) | Method for preparing copolymer comprising 4-hydroxybutyrate, 2-hydroxybutyrate and lactate as repeating unit with increased lactate content | |
| KR102060641B1 (en) | Liquid biopolymer, use thereof and preparation method thereof | |
| KR102091259B1 (en) | Method for controlling polyhydroxyalkanoate using sequence variation in 5'-untranslated region | |
| KR102088502B1 (en) | Copolymer comprising 4-hydroxybutyrate, 3-hydroxybutyrate, 2-hydroxybutyrate and lactate as repeating unit and method for preparing the same | |
| KR102318930B1 (en) | Adhesive Composition Comprising Polyhydroxyalkanoate | |
| KR102497785B1 (en) | Recombinant microorganism and method for preparing copolymer comprising 2-hydroxybutyrate and lactate | |
| KR101260187B1 (en) | Recombinant microorganism able to produce polylactate or polylactate copolymer from glycerol and method for producing polylactate or polylactate copolymer from glycerol using the same | |
| KR102009420B1 (en) | Method for preparing copolymer comprising 4-hydroxybutyrate and lactate as repeating unit using glucose | |
| KR101293904B1 (en) | Recombinant microorganism capable of producing polylactate or polylactate copolymer from xylose and method for producing polylactate or polylactate copolymer from xylose using the same | |
| KR20250018302A (en) | Recombinant Escherichia coli strain for production of P(3HP-co-3HB) with high yield and method for producing biodegradable P(3HP-co-3HB) using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |